Biomoda - 500 Beiträge pro Seite

[pennyjoe]

.

habe mir gerade ein paket Biomoda zugelegt

ein tip aus einer zuverlässigen quelle

aktueller preis US$ 0,17 bid - 0,25 ask

kursziel US$ 2,00 auf jahressicht

geht nur über die nasdaq

da es sich um ein otc-papier handelt, gehört es in die höchste risikostufe und jeder muss selbst entscheiden, ob es für sein depot geeignet ist.

.

[pennyjoe]

.

die entwicklung der letzten handelstage ist positiv

http://finance.yahoo.com/q/bc?s=BMOD.OB&t=1d&l=on&z=m&q=l&c=

hier könnt ihr die entwicklung verfolgen

warum es ein vervielfacher sein wird, müßt ihr selber rausfinden

.

[derrest]

Antwort auf Beitrag Nr.: 32.647.671 von pennyjoe am 03.12.07 15:57:03

welche gründe hat denn deine "zuverlässige quelle" angegeben?

[pennyjoe]

Antwort auf Beitrag Nr.: 32.655.070 von derrest am 04.12.07 08:57:12

.

einer der verantwortlichen hätte vor ca 6 monaten mit einem großen aktienpaket die flucht ergriffen, konnte aber mittlerweile dinghaft gemacht werden und der ordentliche geschäftsbetrieb wurde wieder aufgenommen.
es seien alle aktienbestände überprüft und geregelt worden, sodaß die erfolgsgeschichte weitergeschrieben werden kann.

diese infos stammen aus "hörensagen" - eine verantwortung kann nicht übernommen werden


ich bin aufjedenfall drin

.

[derrest]

Antwort auf Beitrag Nr.: 32.660.491 von pennyjoe am 04.12.07 16:00:10

wie kann denn da einer mit aktien abhauen??

und: in den nachrichten ist nichts zu finden, dass der ordentliche geschäftsbetrieb je eingestellt wurde....

... das produkt allerdings ist wirklich sehr vielversprechend...

worauf bezieht sich: erfolgsgeschichte

"hörensagen" - ein kenner? oder eine wilde börsenbriefinfo??

derrest

[pennyjoe]

.

die erfolgsgeschichte bezieht sich auf die "zulassungsreife" bei der FDA
ein aktienpaket kann ein vorstand mit alleinvertretungsvollmacht auf irgendein depot übertragen - ist zwar in meinen augen ziemlich deppert, da der weg nachvollzogen werden kann

aber es gibt soviel kranke hirnies

wichtig ist mir, dass die firma weiterhin zielorientiert arbeitet und die jetzigen entscheider korrekt sind.

.

[pennyjoe]

.

hier kann man sich informieren:

http://finance.yahoo.com/q/h?s=bmod.ob&m=1196789571

viel spass

.

[pennyjoe]

.

in den vergangenen monaten wurden hochkarätige mitarbeiter verpflichtet

.

[pennyjoe]

Biomoda Hires Senior Scientist to Head Research & Development Effort
11/19/2007


ALBUQUERQUE, N.M., Nov. 19 /PRNewswire-FirstCall/ -- Biomoda, Inc. (http://www.biomoda.com) of Albuquerque, NM, announced today Dr. Leo Gomez has joined Biomoda as Director of Research, spearheading the company's research efforts towards commercialization of its assay for the early detection of lung cancer.

Dr. Gomez has coordinated and managed more than 30 medical device, radiopharmaceutical and nuclear research projects over his thirty-year career as a nationally respected senior scientist. Most recently, as Director of Research for TCI Medical headquartered in Albuquerque, Dr. Gomez coordinated research and clinical trials on medical innovations among scientific institutions in the former Soviet Union and the U.S. He worked as a senior scientist at the U.S. Department of Energy's Sandia National Laboratories, Los Alamos National Laboratory and Oak Ridge National Laboratory for twenty-eight years, and was editor of an international environmental journal for more than ten years. The author of numerous articles, Dr. Gomez also served on more than 40 National Technical Review Boards, Advisory Boards and the Board of Directors of scientific, educational and professional organizations.

"Dr. Gomez brings an exceptionally well-suited approach to scientific study and the commercial development of medical breakthroughs such as our early lung cancer detection assay," said John Cousins, President of Biomoda. "His experience and expertise with clinical trials and knowledge and skill with publications will be put to excellent use. Biomoda is poised to begin a myriad of projects that Dr. Gomez directs. His experience will be invaluable."

Dr. Gomez was awarded a Masters of Science in Radiation Biology and Health Physics and a Ph.D. in Radiation Biology from Colorado State University. He holds a Bachelor of Science degree from the University of New Mexico

Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins [phone]

CONTACT: John Cousins of Biomoda, Inc., [phone]

Web site: http://www.biomoda.com/

[Alphatier]

Antwort auf Beitrag Nr.: 32.712.279 von pennyjoe am 10.12.07 11:20:46

Die waren schon mal bei 4,20 US$ (vor ca. 18 Monaten)

Da liegt Musik drin

[pennyjoe]

Antwort auf Beitrag Nr.: 32.714.522 von Alphatier am 10.12.07 14:38:11

.

also ich persönlich wäre mit US$ 2,00 zufrieden

aber das wird wohl einpaar wochen dauern

.

[pennyjoe]

.

hier etwas für die interessierten:


Form 10QSB for BIOMODA INC/NM


--------------------------------------------------------------------------------

19-Nov-2007

Quarterly Report



ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
COMPANY OVERVIEW

Biomoda, Inc. (the "Company") is a development stage company incorporated in the state of New Mexico on January 3, 1990. The Company's general focus is on discovery, development, manufacture and marketing of proprietary medical diagnostic and treatment products used to treat life threatening and other serious diseases. Our primary focus is creating diagnostic solutions for early detection and clinical management of cancer.

On July 19, 2006, the Company closed its offering of up to 6,000,000 shares of its common stock pursuant to a registration statement on Form SB-2 (the "Registration Statement") under the Securities Act of 1933, as amended, declared effective on February 11, 2005. The Company's market maker filed Form 211 with NASD Regulation to initiate quotations in its common stock on the OTC Bulletin Board. The request was cleared on October 19, 2006.

PLAN OF OPERATION

Our plan of operation for the next twelve months is to complete the validation studies for our lung cancer assay, design our diagnostic product, choose our contract manufacturing partner, manufacture our initial batches, register our product with the FDA and then with European authorities for our CE mark, and begin marketing to reference labs in the US and Europe. To that end, we have contracted with Quintiles Consulting for regulatory consulting, TriCore Reference Laboratories for assay preparation, Averion International Corporation for clinical services, and Clinical Research Center of Cape Cod. to provide lung sputum samples. We intend to have initial revenues in the last quarter of 2008. The Company is raising funds from the sale of restricted common stock through a Regulation S Offering and is assessing various offering scenarios.

Our initial product is a diagnostic test for lung cancer that will be performed out of body by using a sputum sample from the patient. Our test does not require any invasive sample taking. The sample will be sent to a clinical lab where the procedure will be performed to determine the presence, or not, of lung cancer or precancerous cells. Our diagnostic test can be used for other cell samples and we intend to create and market products to diagnose and screen for other prevalent cancers such as breast, cervical, bladder, and colorectal. We have determined that our initial markets will be the developed nations of Europe, North America and Japan. This has been determined on the basis of available healthcare delivery and payer infrastructure. Japan is leading the world, and has instituted a nationwide lung cancer-screening program. We also intend to sell our product in additional markets throughout the world such as India, Brazil and South America, Asia and Russia. We will market different product formats based on the region of the world.



--------------------------------------------------------------------------------

Table of Contents
In addition to augmenting laboratory research and development, management plans to further strengthen the corporate infrastructure of the Company to adequately manage the future growth and success of our operations. Management expects to hire additional personnel and enter into consulting and collaborative arrangements over the next twelve months as needed to continue to strengthen and enhance the effectiveness of implementing our plan as we grow.

The Company's Research and Development facilities are located on Kirtland Air Force Base in Albuquerque, New Mexico. R&D is housed in approximately 2500 square feet that includes two state-of-the-art laboratories where primary research, assay validation and commercialization work is being conducted.

Over the next twelve months management will continuously evaluate and develop our business plan which includes assessing the technology we utilize and the markets we intend to serve and evaluating the prospect of expanding into additional products and markets as business conditions warrant. In connection with this continual evaluation, management will also look at taking actions designed to mitigate any and all risks associated with our business plan.

In January 2005, the U.S. Patent Office awarded a Patent to Biomoda researchers entitled "Compositions and Methods for Detecting Precancerous Conditions in Cells and Tissue Samples using 5, 10, 15, 20 Tetrakis (Carboxyphenyl) Porphine". This Patent brings a significant addition to Biomoda's Patent portfolio and expands the Company's intellectual property to include cancer screening as a compliment to Biomoda's existing technology. Biomoda is completing the formal filing for a continuation for this Patent based on research currently underway by researchers at Biomoda. The Company believes its goal to further strengthen and expand its intellectual property portfolio will be significantly enhanced by these developments. Biomoda, Inc.'s R&D Division has successfully completed the first clinical validation of the company's development stage assay for lung cancer. These results indicate its ability to differentiate lung cancer patients, heavy smokers, and normal individuals.

RESULTS OF OPERATIONS

Due to our limited operating history, we believe that period-to-period comparisons of our results of operations are not fully meaningful and should not be relied upon as an indication of future performance.

Comparison of the three months ended September 30, 2007 and 2006

REVENUE. As of September 30, 2007, there have been no significant revenues since inception.

PRODUCT DEVELOPMENT. Product development expenses consist primarily of personnel expenses and consulting fees. Research and development, including payroll costs and other technical costs decreased to $15,492 in the three months ended September 30, 2007 from $110,877 in the three months ended September 30, 2006. The Company believes that continued investment in product development is critical to attaining our strategic objectives and, as a result, we expect expenses such as clinical studies and collaborations to increase significantly in the next year. We expense product development costs as they are incurred.

GENERAL AND ADMINISTRATIVE General and administrative expenses consist of expenses for executive and administrative personnel, facilities, professional services, travel and general corporate activities. General and administrative costs, taken together with professional fees, increased to $55,242 in the three months ended September 30, 2007 from $28,737 in the three months ended September 30, 2006. We expect general and administrative costs to increase in the future as our business prospects develop and we will require more staff. The costs associated with being a publicly traded company and future strategic acquisitions will also be a contributing factor to increases in this expense.

OTHER INCOME (EXPENSE) Other income (expense) in these periods consists of interest expense, which decreased to $25,118 in the three months ended September 30, 2007 from $27,317 in the three months ended September 30, 2006 due to lower balance in related party debt.



--------------------------------------------------------------------------------

Table of Contents
Comparison of the nine months ended September 30, 2007 and 2006

PRODUCT DEVELOPMENT. Product development expenses consist primarily of personnel expenses and consulting fees. Research and development, including payroll costs and other technical costs increased to $807,308 in the nine months ended September 30, 2007 from $369,602 in the nine months ended September 30, 2006 due to significant stock issuance for services. The Company believes that continued investment in product development is critical to attaining our strategic objectives and, as a result, we expect expenses such as clinical studies and collaborations to increase significantly in the next year. We expense product development costs as they are incurred.

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of expenses for executive and administrative personnel, facilities, professional services, travel and general corporate activities. General and administrative costs, taken together with professional fees, increased to $1,656,427 in the nine months ended September 30, 2007 from $166,581 in the nine months ended September 30, 2006. This increase was due primarily to $1,482,102 of stock issued for services, which is divided between this classification and research expenses, above, and increased legal fees. We expect general and administrative costs to increase in the future as our business prospects develop and we will require more staff. The costs associated with being a publicly traded company and future strategic acquisitions will also be a contributing factor to increases in this expense.

OTHER INCOME (EXPENSE). Other income (expense) in these periods consists of interest expense, which increased to $76,778 in the nine months ended September 30, 2007 from $76,459 in the nine months ended September 30, 2006. Additionally, we recorded $16,064 gain on forgiveness of debt in 2006.

LIQUIDITY AND CAPITAL RESOURCES

Since inception, we have funded our operations through private placement of equity securities and loans from Advanced Optics Electronics, Inc ("ADOT"). As of September 30, 2007, we have raised net proceeds of approximately $4,915,000 from these sources.

Product development expenditures, including personnel expense, and general and administrative expense approximated $2,463,735 for the nine months ended September 30, 2007. Funds for operations, product development and capital expenditures were provided from a line of credit agreement with ADOT and the sale of restricted company stock. The Company will require substantial additional funding for continuing research and development, obtaining regulatory approval and for the commercialization of its products.

Management believes that sales of securities will provide adequate liquidity and capital resources to meet the anticipated development stage requirements through the end of 2007. In addition, At that time it is anticipated that sales of our initial screening product will begin and contribute to operating revenues. It is anticipated that these sales will provide the additional capital resources to fund the proportionately higher working capital requirements of production and sales initiatives and continued product development for second-generation diagnostic and therapeutic products.

There is no assurance that the Company will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtainable on terms satisfactory to the Company. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

INFLATION

Management believes that inflation has not had a material effect on the Company's results of operations.



--------------------------------------------------------------------------------

Table of Contents

[pennyjoe]

.

auch nicht uninteressant - es gibt nur 15,7 mio aktien

aktuelle marktkapitalisierung US$ 2,67 mio

wenn's hier rappelt, dann richtig

.

[pennyjoe]

.

Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer.
Santa Fe, N.M., October 2, 2007 -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , testified Monday before the New Mexico State Legislature’s Interim Tobacco Settlement Committee in support of the lawmakers’ $1.3 million proposal for funding a clinical study using the company’s assay for early lung cancer detection.

The New Mexico legislature last year appropriated $350,000 to fund a clinical study that will begin later this year to screen veterans for lung cancer at its earliest stages. If approved, the $1.3 million funding proposal for 2008 would be a continuation of existing funding for the clinical study and will be considered during the state’s 30-day legislative session beginning January 15, 2008.

“Members of the Tobacco Settlement Committee are at the forefront of funding essential studies to develop a nationwide screening protocol for lung cancer that ultimately will result in saving millions of lives,” said Cousins. “We look forward to being part of this breakthrough effort and we are thrilled to be helping our veterans in this process. The men and women who served our country deserve the very best healthcare. This clinical work will provide just that.”

Doug Craft, President of the Black Veterans Association of New Mexico, testified in support of Biomoda’s efforts. “We are grateful for this opportunity and plan to work very hard to let our brothers and sisters who served in the military learn about, and be part of, this important opportunity that not only will further essential research, but also save lives.”

Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Cautionary Statement: Investors should be aware that trading in the company’s stock through market makers and quotation on the OTC Bulletin Board entails risk. Due in part to the decreased trading price of our stock and reduced analyst coverage, the trading price may change quickly, and market makers may not be able to execute trades quickly. Please contact your broker if you have further questions about executing trades. “Safe Harbor” Statement: This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

[Alphatier]

Antwort auf Beitrag Nr.: 32.736.982 von pennyjoe am 12.12.07 11:49:37

Die neueste Meldung:


ALBUQUERQUE, N.M., Dec. 12 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD - News; http://www.biomoda.com) of Albuquerque, NM, and New Mexico Institute of Mining and Technology (New Mexico Tech at http://www.nmt.edu) reached an agreement today to collaborate on clinical studies and the development of specialized image recognition technology as part of the company's commercialization of its assay for the early detection of lung cancer.


New Mexico Tech, in Socorro, New Mexico, is a world leader in many areas of research, including biomedical, hydrology, astrophysics, atmospheric physics, geophysics, homeland security, information technology, geosciences, energetic materials engineering, and petroleum recovery. The university specializes in research, focusing on science, engineering and related fields.

"This new research and development collaboration between Biomoda and New Mexico Tech will enable university researchers and students to directly participate in the testing and development of cutting-edge technology which will soon be deployed in the fight against cancer," said Daniel H. Lopez, president of New Mexico Tech. "This new joint venture forged between a public university and a private business promises to be a win-win situation for all involved."

"I am particularly pleased to announce our partnership with such a strong research and engineering partner as New Mexico Tech as we move towards commercialization of Biomoda's early cancer diagnostic technology," said John Cousins, President of Biomoda. "The scientists at New Mexico Tech offer a wide range of expertise in biomedical and engineering research programs that will be applied immediately in development of engineering technology for image recognition that is targeted at broad-based screening of large populations for lung cancer."

Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins

[phone]

[pennyjoe]

Antwort auf Beitrag Nr.: 32.740.296 von Alphatier am 12.12.07 16:02:43

.

anscheinend wird die biomoda in fachkreisen mit ihren patenten sehr ernst genommen

.

[Alphatier]

Antwort auf Beitrag Nr.: 32.757.375 von pennyjoe am 13.12.07 18:24:13

Hier noch eine Meldung aus dem Januar;

ALBUQUERQUE, N.M. -- Biomoda, Inc. (OTCBB: BMOD) of Albuquerque, NM, maker of early lung cancerlung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. By far the most common source of these insults is tobacco smoke, which is responsible for about 85% of U.S. lung cancer deaths (see smoking).
..... Click the link for more information. detection testing and other cancer diagnostic technology, announced its agreement with Northport Associates to direct Biomoda's government and public affairs efforts. Northport will spearhead Biomoda's state and federal lobbying to secure funding for its programs to screen military personnel and veterans for lung cancer using Biomoda's proprietary assay. Biomoda trades on NASDAQ's OTC Bulletin Board: ticker symbol "BMOD".

"We are extremely proud to assist Biomoda when speaking with state and federal lawmakers in support of the company's medical breakthrough technology," said Maria Zannes, a principal of Northport Associates. Ms. Zannes, an attorney, and Northport principal Thomas Peacock will manage communications and outreach. Each have more than 30 years experience on Capitol Hill, the White House and private industry directing public policy issues.

"Over the next six years, the Lung Cancer Alliance estimates that a million Americans will die from lung cancer," said Mr. Peacock, who will be managing federal communication with the Congress and the Administration. "Biomoda's technology can greatly help in the battle against cancer by providing early detection for better treatment. Several proposals under legislative review will work with active military and veterans to provide broad-base cancer screening for these brave men and women who now face an even greater risk from lung cancer."

The Mayo Clinic, one of the premier healthcare and research institutions in the world, and the Company are jointly conducting a broad validation study of Biomoda's patented technology, a non-invasive cytology based lung cancer diagnostic assay. Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum. Cancerous cells glow red under fluorescent light to allow detection under a microscope.

The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

"Safe Harbor" Statement: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

[Alphatier]

Antwort auf Beitrag Nr.: 32.736.982 von pennyjoe am 12.12.07 11:49:37

Hier die Vorgeschichte zum Biomoda-Fall:

15-Aug-2007

Change in Directors or Principal Officers, Other Events



Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Leslie S. Robins was removed for cause from the board of directors (the "Board") of Biomoda, Inc. (the "Company") at a special meeting of the Board held on Tuesday August 7, 2007. The Board removed Mr. Robins from the Board due to his actions related to the unauthorized issuance of shares of the Company's common stock and unauthorized use of Company funds. Mr. Robins did not serve on any committees of the Board.

On August 14, 2007, the Board also ratified the President's termination of Mr. Robins as Vice President and Secretary of Biomoda effective July 21, 2007. Mr. Robins was terminated for cause as described above.

The Company has furnished Mr. Robins a copy of this Form 8-K and will file any letter received from Mr. Robins on this matter within two business days of receipt of such letter.

Dr. Albert Goodman resigned from the Board effective August 1, 2007. Dr. Goodman did not serve on any committees of the Board





Item 8.01 Other Events
The Company previously conducted an offering of up to 6,000,000 shares of its common stock pursuant to a registration statement on Form SB-2, File No. 333-90738, and Form SB-2MEF, File No. 333-122539. This registration statement became stale on November 4, 2005, prior to selling any shares under this registered offering. The Board is currently investigating the issuance of the following shares of common stock purportedly under the SB-2 registration statement pursuant to Mr. Robins' sole and unauthorized direction: 343,000 shares on or about June 5, 2007, 230,000 shares on or about June 8, 2007, 500,000 shares on or about June 25, 2007, 90,000 shares on or about July 11, 2007, 50,000 shares on or about July 11, 2007, and 555,000 shares on or about July 13, 2007. Based upon the Board's initial investigation, all of such shares were issued without registration under the Securities Act of 1933, as amended, or any exemption therefrom. As a result, such shares were issued in violation of the Securities Act of 1933, as amended. Such violations may subject the Company to enforcement action by the Securities and Exchange Commission.

The Company continues to conduct its investigation of the issuance of such securities and other actions of Mr. Robins, as well as the Company's controls and procedures related to securities issuances and asset management.

On July 25, 2007, Leslie Robins filed a Complaint for Declaratory Judgment and Application for Temporary Restraining Order/ Preliminary and Permanent Injunction against Biomoda, John J. Cousins and Maria Zannes (collectively, the "Biomoda Parties"), Cause No. CB-2007-06529, Second Judicial District Court, State of New Mexico. Also listed as nominal Plaintiffs were Advanced Optics Electronics, Inc. and Ari Maayan. The lawsuit alleges that the Biomoda Parties are attempting a hostile takeover of Biomoda by unlawfully removing Mr. Robins. At oral argument held on August 7, 2007, the Court denied Plaintiffs' motion for a temporary restraining order that sought to enjoin the removal of Mr. Robins from the Board and denied Mr. Robins' motion to place Biomoda in receivership. The Biomoda Parties filed an answer and counterclaim to this lawsuit on August 13, 2007, in which they denied all of the Plaintiff's substantive claims and provided affirmative defenses. In addition, the Biomoda Parties counterclaimed that Mr. Robins actions in (i) directing the unauthorized and unregistered sale of securities in violation of the Securities Act of 1933, as amended (ii) improper diversion of cash and other assets from Biomoda, (iii) improper dumping of Biomoda shares into the public markets, and (iv) defamation of officers and directors of Biomoda, has materially harmed Biomoda. The Biomoda Plaintiffs are seeking a temporary restraining order, preliminary injunction and permanent injunction preventing Mr. Robins from acting in any capacity on behalf of Biomoda and seeking to freeze Mr. Robins bank accounts. The Biomoda Plaintiffs also seek to recover monies and assets improperly taken from Biomoda.

[kochilein]

Antwort auf Beitrag Nr.: 32.773.388 von Alphatier am 15.12.07 12:46:34

Hallo,

halte auch einige Anteile an Biomoda.
Habe die Info, dass ein Listing in Frankfurt geplant sei !
Weiß jemand etwas darüber ?

[Alphatier]

Antwort auf Beitrag Nr.: 32.777.376 von kochilein am 15.12.07 21:14:23

Hallo,
das Listing in Frankfrut ist in Vorbereitung. Soweit ich weiss, hätte es noch im Dezember erfolgen sollen. Ich denke, das wurde erstmal aufs nächste Jahr verschoben.

[derrest]

Antwort auf Beitrag Nr.: 32.780.551 von Alphatier am 16.12.07 11:08:28

woher weißt du das??

[Alphatier]

Antwort auf Beitrag Nr.: 32.787.697 von derrest am 17.12.07 08:38:24

Das stammt aus der Ecke, über die ich vor Monaten die Aktien bezogen habe: ein US-Broker und ein Schweizer Finanzberater.
Inwieweit das der Realität entspricht, kann ich persönlich nicht einschätzen.
Für viele Unternehmen ist eine Zweitnotierung ja nicht unbedingt rentabel.

[pennyjoe]

.

ein listing in frankfurt wäre für die aktien schlichtweg eine katastrophe

da es nur 15,7 mio von dieser seltenen spezies gibt, würde das bedeuten, dass sie von depot zu depot gejagt werden - rücksichtslos umgeschichtet - vom geld getrieben - gewachsene gemeinschaften z.b. 10.000er pakete durch steigende preise auseinandergerissen, nicht wissend ob sie sich jemals wiedersehen .......... von konitinent zu kontinent gejagt von gierigen anlegern ......

genug geheult ... ich fänd's richtig klasse

.

[Alphatier]

Antwort auf Beitrag Nr.: 32.789.119 von pennyjoe am 17.12.07 11:18:29

[pennyjoe]

.

eine schöne aufgabe für's neue jahr

Currently, there are no commercially available methods of detecting lung cancer at the pre-cancerous stage and there is no FDA approved screen for lung cancer. We are preparing for additional clinical trials and commercialization for extreme early lung cancer detection, thus putting Biomoda on the leading edge of the research curve.

wenn sie dafür die FDA zulassung kriegen, hat sich das warten gelohnt.

.

[Alphatier]

Antwort auf Beitrag Nr.: 32.812.608 von pennyjoe am 19.12.07 11:24:29

Die waren ja schon mal knapp davor. Deswegen der historische Höchststand von 4,20 US Dollar

[pennyjoe]

Antwort auf Beitrag Nr.: 32.813.684 von Alphatier am 19.12.07 12:54:47

.

und woran ist es gescheitert?

.

[pennyjoe]

.

na dann wollen wir mal hoffen, dass es für biomoda das jahr des erwarteten durchbruchs wird

.

[Alphatier]

Antwort auf Beitrag Nr.: 32.915.407 von pennyjoe am 02.01.08 15:07:30

Geht schon wieder aufwärts mit dem Schätzchen. Waren wohl im Weihnachtsurlaub.

[pennyjoe]

Antwort auf Beitrag Nr.: 32.916.281 von Alphatier am 02.01.08 16:22:56

.

+ 33,3% schööön

.

[MaatMod]

!

Dieser Beitrag wurde moderiert.

[pennyjoe]

.

danke an den mod, der den thread enthistorisiert hat

es gibt news:

FDA Reviewing Biomoda Submission for Cancer Screening Study
Monday August 4, 1:57 pm ET


ALBUQUERQUE, N.M., Aug. 4 /PRNewswire-FirstCall/ -- Biomoda, Inc., a development stage medical diagnostics company, submitted to the FDA a pre-IDE (Investigational Device Exemption) protocol for a clinical study using Biomoda's proprietary assay for detection of early lung cancer in veterans. The New Mexico state legislature allocated more than $1.6 million over two years towards the study that will screen more than 2000 veterans.
"This is an essential step in study development," said John Cousins, President of Biomoda. "Approval by the FDA of the study design this year allows us to move forward quickly to prove the efficacy of the assay. Approval by the Agency of the results of this study that we expect early next year will provide us the ability to market our assay commercially."

Biomoda's patented technology is designed for early lung cancer screening of large populations at a reasonable cost. The non-invasive test, originally developed at Los Alamos National Laboratory, allows clinicians to identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells in the sputum exposed to the assay glow red under fluorescent light and can be detected under a microscope.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a two-phase study of the state's veterans. The initial phase will screen 225 veterans; a second phase will test more than 2000 veterans for lung cancer using Biomoda's non-invasive patented assay.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15%; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16% of lung cancer cases are diagnosed at this early stage.


vielleicht wird aus diesem frosch doch noch ein prinz

.

[pennyjoe]

.

bin ich hier der einzige, der in biomoda investiert ist

.

[Alphatier]

Antwort auf Beitrag Nr.: 34.680.313 von pennyjoe am 08.08.08 10:37:24

Hallo pennyjoe,

ich bin schon noch da. Die Meldung hab ich auch gesehen, und wenn die FDA die Sache tatsächlich für gut beheißt, ist für Biomoda "Polen offen". Könnte ne echte Kurs-Rakete werden, wenn nichts schief läuft

[pennyjoe]

.

da bin ich ja froh, dass ich nicht alleine an die chancen dieser aktie glaube.
wenn die amerikanische gesundheitsbehörde die genehmigung erteilt, wird es ein vervielfacher - ist schon klar.

na denn toi toi toi ....

.

[Alphatier]

40% im Plus
Bei zwar geringen Umsätzen, aber immerhin nach oben

[pennyjoe]

.

ich denke wir brauchen noch etwas geduld - aber wenn's rappelt, dann richtig

.

[pennyjoe]

.

Clinical Lab Products Magazine Features Biomoda
9/2/2008 12:53 PM - PR Newswire

ALBUQUERQUE, N.M., Sept 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Clinical Lab Products magazine features Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) and its proprietary early lung cancer screening assay as one of the more promising advances in the cancer diagnostic technology. The August national magazine article (http://www.clpmag.com/issues/articles/2008-08_01.asp) makes particular note of the assay's simplicity that leads to large scale screening of lung cancer using automated equipment.

"The ease in use of the assay is apparent, as well as the benefit of a test that detects cancer at its earliest stage," said John Cousins, President of Biomoda. Cancer caught at earlier stages is essential for improved outcomes.

Biomoda's patented technology is designed for early lung cancer screening of large populations at a reasonable cost. The non-invasive test, originally developed at Los Alamos National Laboratory, allows clinicians to identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells in the sputum exposed to the assay glow red under fluorescent light and can be detected under a microscope.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a two-phase study of the state's veterans. The initial phase will screen 225 veterans; a second phase will test more than 2000 veterans for lung cancer using Biomoda's non-invasive patented assay.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15%; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16% of lung cancer cases are diagnosed at this early stage.

For more information contact: John Cousins 505-821-0875 [e-mail]

Forward Looking Statement

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of BIOMODA's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. BIOMODA, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in BIOMODA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

SOURCE Biomoda, Inc.

http://www.biomoda.com

Copyright (C) 2008 PR Newswire. All rights reserved

[pennyjoe]

.

langsam könnten aber mal wieder news kommen

am besten wäre natürlich die fsa-zulassung

.

[pennyjoe]

.

U.S. Patent Office Grants Biomoda Registration for Trademarks
9/22/2008 1:58 PM - PR Newswire

ALBUQUERQUE, N.M., Sept 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, expanded its intellectual property portfolio with approval from the U.S. Patent and Trademark Office for its Trademarks CyDx(R) and CyPath(R).

"We are pleased to receive these two new trademark protected names for our product portfolio," said John Cousins, Biomoda president. "It is a big milestone for us to achieve sales and meet the metrics for getting these registered trademarks. CyDx(R) and CyPath(R) are particularly powerful and memorable names and will help to differentiate our cancer diagnostic assays."

Biomoda's innovative, non-invasive technology is designed for early lung cancer screening of large populations at a reasonable cost. With the technology, clinicians can identify cancerous or aberrant cells extracted from samples of sputum. When exposed to CyPath(R), cancerous cells in sputum glow red under fluorescent light and can be detected under a microscope.

Biomoda, with funding provided through the New Mexico Institute of Mining and Technology and the New Mexico Department of Veterans Services, is currently conducting a clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the veterans. The New Mexico state legislature allocated $1.6 million in funding for the screening program.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.

Biomoda's technology was originally developed at Los Alamos National Laboratory.

For more information contact: John Cousins Biomoda, Inc. 505-821-0875 [e-mail]

[pennyjoe]

.

.

[Alphatier]

Wenigstens bei Biomoda tut sich was Positives:

Press Release Source: Biomoda, Inc.

U.S. Patent Office Grants Biomoda Registration for Trademarks
Monday September 22, 1:58 pm ET

ALBUQUERQUE, N.M., Sept. 22 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD - News; http://www.biomoda.com), a development stage medical diagnostics company, expanded its intellectual property portfolio with approval from the U.S. Patent and Trademark Office for its Trademarks CyDx® and CyPath®.
"We are pleased to receive these two new trademark protected names for our product portfolio," said John Cousins, Biomoda president. "It is a big milestone for us to achieve sales and meet the metrics for getting these registered trademarks. CyDx® and CyPath® are particularly powerful and memorable names and will help to differentiate our cancer diagnostic assays."

Biomoda's innovative, non-invasive technology is designed for early lung cancer screening of large populations at a reasonable cost. With the technology, clinicians can identify cancerous or aberrant cells extracted from samples of sputum. When exposed to CyPath®, cancerous cells in sputum glow red under fluorescent light and can be detected under a microscope.

Biomoda, with funding provided through the New Mexico Institute of Mining and Technology and the New Mexico Department of Veterans Services, is currently conducting a clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the veterans. The New Mexico state legislature allocated $1.6 million in funding for the screening program.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.

[pennyjoe]

.

es gibt news


Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report
11/3/2008 1:47 PM - PR Newswire

ALBUQUERQUE, N.M., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, announced today that BUYINS.NET, http://www.buyins.net, is initiating coverage of Biomoda after releasing the latest short sale data to October 2008. From November 2006 to October 2008 approximately 13.6 million total aggregate shares of BMOD have traded for a total dollar value of nearly $3.6 million. The total aggregate number of shares shorted in this time period is approximately 1 million shares. The BMOD SqueezeTrigger price of $0.27 is the volume weighted average short price of all short selling in BMOD. The first of several short squeezes is expected to begin when shares of BMOD close above $0.05, where approximately 16,000 shares have been shorted. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

Month Total Vol. Short Vol. Avg. Price Short $ Value November '06 1,350 104 $3.50 $364 December 12,500 963 $2.90 $2,791 January '07 476,123 36,661 $1.77 $64,982 February 306,044 23,565 $0.96 $22,682 March 381,010 29,338 $0.75 $22,077 April 442,725 34,090 $0.65 $21,988 May 1,092,498 84,122 $0.49 $41,430 June 1,750,488 134,788 $0.23 $31,001 July 2,658,260 204,686 $0.12 $23,539 August 1,565,381 120,534 $0.06 $7,774 September 423,743 32,628 $0.09 $3,018 October 757,954 58,362 $0.13 $7,663 November 703,878 54,199 $0.20 $10,840 December 291,895 22,476 $0.21 $4,608 January '08 233,309 17,965 $0.15 $2,671 February 195,609 15,062 $0.11 $1,627 March 762,900 58,743 $0.07 $4,042 April 299,200 23,038 $0.06 $1,451 May 326,100 25,110 $0.07 $1,665 June 361,240 27,815 $0.06 $1,766 July 164,700 12,682 $0.06 $774 August 178,932 13,778 $0.06 $861 September 179,350 13,810 $0.05 $621 October 31,409 2,418 $0.05 $118 Total: 13,596,598 1,046,938 $0.27 $280,353 * short volume is approximated using a proprietary algorithm. ** average short price is calculated using a volume weighted average short price. *** short volume is the total short trade volume and does not account for covers. Market Maker Friction Factor is shown in the chart below: Date Change % BuyVol Buy% SellVol Sell% NetVol Friction 10/29/2008 -0.02 -40.00% 0 0.00% 500 100.00% -500 -250 10/28/2008 0 0.00% 0 0.00% 0 0.00% 0 0 10/27/2008 -0.01 -16.67% 0 0.00% 5,000 100.00 -5,000 -5000 10/24/2008 0 0.00% 0 0.00% 0 0.00% 0 0
Analysis of the Friction Factor chart above shows that in the 4 trading days preceding this report that market makers have been making a normal market in shares of BMOD. The Friction Factor displays how many more shares of buying than selling are required to move BMOD higher by one cent or how many more shares of selling than buying moves BMOD lower by 1 cent. The Friction Factor is relatively low at this time so shares can be expected to move quickly should shares of BMOD close above the first SqueezeTrigger levels between $.05 and $.07. Buyins.net will continue its daily market surveillance of BMOD to ensure a fair and orderly market is being made in its shares.

The chart below shows the broker dealers acting as market makers in sharesof BMOD. % of Total Rank Market Maker Volume Jan - Sep 2008 Volume 1 Knight Equity Markets 1,106,582 41 2 UBS Securities 502,143 18 3 Domestic Securities 257,200 9 4 E*Trade Capital Markets 182,665 6 5 Hudson Securities 154,800 5
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Biomoda, Inc. has paid $995 per month to purchase data for information provided in this six monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SOURCE Biomoda, Inc.

http://www.biomoda.com

Copyright (C) 2008 PR Newswire. All rights reserved
<< Previous | Next >>






Quotes delayed at least 20 minutes for NYSE/AMEX, 15 minutes for other exchanges.
© 2008 Stockhouse Inc.Terms & Conditions. Privacy Policy. News provided by Comtex.




FREE REPORTS

[pennyjoe]

.

gestern + 100%

.

[pennyjoe]

.

heute schon wieder + 50%

d.h. seit vorgestern + 200%

.

[Alphatier]

Antwort auf Beitrag Nr.: 36.036.140 von pennyjoe am 21.11.08 17:58:25

Press Release


NM Tech, Biomoda Win Legislative Support for Lung Cancer Screening
Wednesday December 3, 1:42 pm ET


SANTA FE, NM--(MARKET WIRE)--Dec 3, 2008 -- The New Mexico State Legislature's Interim Tobacco Settlement Committee has recommended $730,000 in funding to continue a pilot program to screen veterans for early-stage lung cancer. The request in favor of the clinical study administered by the New Mexico Department of Veterans Services (NMDVS) came from the New Mexico Institute of Mining and Technology (NM Tech) and Biomoda, Inc. (OTC BB:BMOD.OB - News), a medical diagnostics company based in Albuquerque and focused on early detection of cancer.

Biomoda President John Cousins joined NMDVS Secretary John Garcia and Dr. Daniel H. López, President of NM Tech, to address the Committee in support of the NMDVS study based on Biomoda's proprietary assay for early detection of lung cancer. The Committee's vote is the first step toward an appropriation in the state's 2009 budget. Since 2006, the Legislature has appropriated a total of $1.65 million for the study.

"Data from the New Mexico veterans study is an important step forward in the development of a broad-scale screening protocol that will ultimately save millions of lives," Cousins said. "Lung cancer is the leading cause of cancer death and a huge drain on available dollars for health care. Members of the Tobacco Settlement Committee understand how important it is to have a commercially viable, inexpensive, accurate diagnostic for early detection."

Biomoda's preliminary internal testing data has been reviewed by the U.S. Food and Drug Administration (FDA) in support of the NMDVS clinical study, and the clinical trial has been expanded to include up to 2,000 patients. The patient population for the study will be drawn from veterans of the U.S. armed forces who are 25 percent more likely to develop lung cancer and die from the disease than the general population.

Biomoda and NM Tech are collaborating on efforts to bring Biomoda's diagnostic for early-stage lung cancer screening to market. Scientists and engineers at NM Tech are developing specialized image recognition technology that will speed the commercialization of the technology.

Biomoda's non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light. The cytology-based assay is designed for cancer screening of large populations at a reasonable cost with expected commercial accuracy of at least 90 percent.

[pennyjoe]

.

es gibt neuigkeiten:

NM Tech, Biomoda Win Legislative Support for Lung Cancer Screening
Santa Fe, NM (December 1, 2008) – The New Mexico State Legislature’s Interim Tobacco Settlement Committee has recommended $730,000 in funding to continue a pilot program to screen veterans for early-stage lung cancer. The request in favor of the clinical study administered by the New Mexico Department of Veterans Services (NMDVS) came from the New Mexico Institute of Mining and Technology (NM Tech) and Biomoda, Inc. (OTCBB: BMOD), a medical diagnostics company based in Albuquerque and focused on early detection of cancer.

Biomoda President John Cousins joined NMDVS Secretary John Garcia and Dr. Daniel H. López, President of NM Tech, to address the Committee in support of the NMDVS study based on Biomoda’s proprietary assay for early detection of lung cancer. The Committee’s vote is the first step toward an appropriation in the state’s 2009 budget. Since 2006, the Legislature has appropriated a total of $1.65 million for the study.

“Data from the New Mexico veterans study is an important step forward in the development of a broad-scale screening protocol that will ultimately save millions of lives,” Cousins said. “Lung cancer is the leading cause of cancer death and a huge drain on available dollars for health care. Members of the Tobacco Settlement Committee understand how important it is to have a commercially viable, inexpensive, accurate diagnostic for early detection.”

Biomoda’s preliminary internal testing data has been reviewed by the U.S. Food and Drug Administration (FDA) in support of the NMDVS clinical study, and the clinical trial has been expanded to include up to 2,000 patients. The patient population for the study will be drawn from veterans of the U.S. armed forces who are 25 percent more likely to develop lung cancer and die from the disease than the general population.

Biomoda and NM Tech are collaborating on efforts to bring Biomoda’s diagnostic for early-stage lung cancer screening to market. Scientists and engineers at NM Tech are developing specialized image recognition technology that will speed the commercialization of the technology.

Biomoda’s non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light. The cytology-based assay is designed for cancer screening of large populations at a reasonable cost with expected commercial accuracy of at least 90 percent.

[Alphatier]

Wieder News:


Press Release Source: Biomoda, Inc.


Biomoda Approved to Begin Screening Veterans for Lung Cancer
Monday March 9, 9:00 am ET


ALBUQUERQUE, NM--(MARKET WIRE)--Mar 9, 2009 -- Biomoda, Inc. (OTC BB:BMOD.OB - News), a medical diagnostics company based in Albuquerque, received approval from an independent Institutional Review Board (IRB) to begin Phase I clinical trials of its cytology-based screening technology for early detection of cancer.
ADVERTISEMENT


IRB review protects research subjects by reviewing the study protocol to make sure it adheres to U.S. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services regulations, that risks to participants are minimized and acceptable in light of the possible benefits, that the informed consent document is accurate, and that the research is conducted in an ethical manner.

Citing the IRB's approval of Biomoda's protocol as a significant step forward, Biomoda President and CEO John Cousins said, "This not only launches our Phase I clinical study, but it also puts us in a position to have a meaningful impact on people's lives today. Our initial study is directed at military veterans who are at high risk for developing lung cancer. If our screening reveals early-stage cancer in one of our volunteers, that person's chance of being alive five years from now goes from 15 percent to 80 percent, all because of early diagnosis and treatment." It is our intent in this pilot program to identify five to ten such cases and have a dramatic impact on saving lives here in New Mexico now.

Working closely with the New Mexico Department of Veterans Services and the New Mexico Institute of Mining and Technology, Biomoda will begin recruiting volunteers for the study from New Mexico's veteran population. Volunteers must be "20 pack year" smokers, individuals who have smoked one pack a day for 20 years or two packs a day for 10 years.

The study will initially enroll approximately 200-300 participants who will provide a deep-lung sputum sample under the guidance of a respiratory therapist. Each volunteer will also undergo a computed tomography (CT) scan, currently the standard of care for early detection of lung cancer. Later this year, the study will expand to 2,500 volunteers.

"Our internal testing on a small sample of patients has shown 100 percent accuracy. With the IRB approval, we can now expand that sample to a statistically significant number of patients which we believe will push us to final FDA approval and commercialization," Cousins said.

Dr. Thomas L. Bauer, thoracic surgeon and cancer researcher with the Christiana Care Health System in Delaware, is the national Principal Investigator (PI) overseeing the Biomoda study. Bauer has led several lung and esophageal cancer studies and heads up Christiana's participation in the International Early Lung Cancer Action Program (I-ELCAP). Bauer will work with Dr. Lara Patriquin, a diagnostic radiologist in Albuquerque, who has agreed to serve as the local PI for the study.

Biomoda's non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light. The cytology-based assay is designed for cancer screening of large populations at a reasonable cost with expected commercial accuracy of at least 90 percent.

[pennyjoe]

.

auch die örtliche politik interessiert sich

http://www.biomoda.com/Heinrich.html

.

[Alphatier]

Die sind - was Öffentlichkeitsarbeit angeht - sehr fleißig:

http://www.biomoda.com/timesquare.html

[pennyjoe]

.

New Mexico Tech to Present Biomoda Data At International Lung Cancer Conference
6/16/2009 8:30:27 AM - GlobeNewswire

ALBUQUERQUE, N.M., Jun 16, 2009 (GlobeNewswire via COMTEX News Network) --
The New Mexico Institute of Mining and Technology (NM Tech) will present data from Biomoda, Inc. (OTCBB:BMOD) on its non-invasive, inexpensive and accurate diagnostic test for the early detection of lung cancer at the 13th World Conference on Lung Cancer in San Francisco, CA, July 31 to August 4, 2009.

NM Tech and two affiliated entities, the Institute for Complex Additive Systems Analysis (ICASA) and the Computational Analysis and Network Enterprise Solutions, LLC (CAaNES), are working with Albuquerque-based medical diagnostics company Biomoda, Inc. on the patented assay for early detection of cancer.

Dr. Srinivas Mukkamala, a senior research scientist with ICASA, will present an abstract titled "Non-Intrusive and Extremely Early Detection of Lung Cancer Using TCPP (Biomoda Lab Cultured Lung Cancer Data)," in poster format to the 7,000 lung cancer professionals expected to attend the conference. TCPP, or meso-tetra (4 carboxyphenyl) porphine, is the chemical compound underlying Biomoda's patented diagnostic assay.

Currently in Phase II clinical trials, Biomoda's diagnostic is a porphyrin application that preferentially binds to cancerous or aberrant cells extracted from deep lung sputum samples. Cancerous cells treated with Biomoda's patented CyPath(tm) labeling solution fluoresce red under ultraviolet light.

Mukkamala's presentation at the World Conference on Lung Cancer will focus on the computer modeling and data analysis work ICASA and CAaNES have done with Biomoda's images and data. "Our work will allow Biomoda to automate the screening process, which is a critical step toward making the diagnostic available to large populations," Mukkamala said. "The computer modeling will also enhance the accuracy of the assay."

"The opportunity to present the Biomoda technology to the top clinicians and scientists in our field is a big step forward for us," said John Cousins, Biomoda President and CEO. "Since only 16 percent of lung cancers today are diagnosed early enough to be cured, this audience will understand the tremendous life-saving potential of an easy, non-invasive, inexpensive and, above all, accurate screening tool for lung cancer."

Sponsored by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer is one of the largest international gatherings of professionals in the field, focusing on both research science and advances in the treatment of lung cancer, the leading cause of cancer deaths worldwide.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Biomoda, Inc.

Biomoda, Inc. John Cousins 505.821.0875 [e-mail]

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

[pennyjoe]

.

news von letzter woche über eine aktuelle studie mit veteranen


Over 400 Vets Enroll in Biomoda Lung Cancer Screening Program
6/9/2009 8:30:56 AM - GlobeNewswire

ALBUQUERQUE, N.M., Jun 9, 2009 (GlobeNewswire via COMTEX News Network) --
More than 400 New Mexico veterans have volunteered to participate in a screening program for the early detection of lung cancer based on a non-invasive diagnostic tool developed by Biomoda, Inc. (OTCBB:BMOD) and trademarked under the name CyPath(tm).

"The value of a study like this is two-fold," said John Cousins, Biomoda President and CEO. "We are literally saving lives by identifying early-stage lung cancer in asymptomatic patients at the same time we are gathering the necessary data to receive FDA approval and move the diagnostic into the marketplace."

Cousins reported that preliminary results of the screening program are trending in a positive direction, and several patients have already been referred for medical follow up.

Biomoda expects to screen at least 3,500 participants in multiple sites over the course of the study. The initial focus is on veterans because they are 25 percent more likely to develop the disease and die from it than the general population. Funded by the New Mexico State Legislature and administered by the New Mexico Department of Veterans Services, "this study puts a spotlight on one of the most serious health issues facing the men and women who serve in uniform," Cousins said. "Veterans we meet through our recruiting outreach are really appreciative of the opportunity to participate, to find out early if they have cancer or a pre-cancerous condition when there is still time for successful treatment and recovery."

Unlike other diagnostics, the Biomoda assay is designed for routine screening of large populations at a reasonable cost and high accuracy. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample that is tested for cancer cells in the Biomoda lab. Results are compared to a computed tomography (CT) scan, currently the standard of care for detection of lung cancer, and sputum PAP stains read by leading cytopathologists who are participating in the study as medical partners.

Biomoda's non-invasive diagnostic is based on a patented porphyrin application originally developed at Los Alamos National Laboratory that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples and causes them to fluoresce red under ultraviolet light.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Biomoda, Inc.

Biomoda, Inc. John Cousins 505.821.0875

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

[Alphatier]

Neuigkeiten:


New Mexico Tech to Present Biomoda Data At International Lung Cancer Conference

* On Tuesday June 16, 2009, 8:30 am EDT

ALBUQUERQUE, N.M., June 16, 2009 (GLOBE NEWSWIRE) -- The New Mexico Institute of Mining and Technology (NM Tech) will present data from Biomoda, Inc. (OTC BB:BMOD.OB - News) on its non-invasive, inexpensive and accurate diagnostic test for the early detection of lung cancer at the 13th World Conference on Lung Cancer in San Francisco, CA, July 31 to August 4, 2009.

NM Tech and two affiliated entities, the Institute for Complex Additive Systems Analysis (ICASA) and the Computational Analysis and Network Enterprise Solutions, LLC (CAaNES), are working with Albuquerque-based medical diagnostics company Biomoda, Inc. on the patented assay for early detection of cancer.

Dr. Srinivas Mukkamala, a senior research scientist with ICASA, will present an abstract titled ``Non-Intrusive and Extremely Early Detection of Lung Cancer Using TCPP (Biomoda Lab Cultured Lung Cancer Data),'' in poster format to the 7,000 lung cancer professionals expected to attend the conference. TCPP, or meso-tetra (4 carboxyphenyl) porphine, is the chemical compound underlying Biomoda's patented diagnostic assay.

Currently in Phase II clinical trials, Biomoda's diagnostic is a porphyrin application that preferentially binds to cancerous or aberrant cells extracted from deep lung sputum samples. Cancerous cells treated with Biomoda's patented CyPath(tm) labeling solution fluoresce red under ultraviolet light.

Mukkamala's presentation at the World Conference on Lung Cancer will focus on the computer modeling and data analysis work ICASA and CAaNES have done with Biomoda's images and data. ``Our work will allow Biomoda to automate the screening process, which is a critical step toward making the diagnostic available to large populations,'' Mukkamala said. ``The computer modeling will also enhance the accuracy of the assay.''

``The opportunity to present the Biomoda technology to the top clinicians and scientists in our field is a big step forward for us,'' said John Cousins, Biomoda President and CEO. ``Since only 16 percent of lung cancers today are diagnosed early enough to be cured, this audience will understand the tremendous life-saving potential of an easy, non-invasive, inexpensive and, above all, accurate screening tool for lung cancer.''

Sponsored by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer is one of the largest international gatherings of professionals in the field, focusing on both research science and advances in the treatment of lung cancer, the leading cause of cancer deaths worldwide.

[pennyjoe]

.

das hatten wir schon

.

[Alphatier]

Zwei sehr gelungene Pressebeiträge:

http://www.wallst.net/tools/quote/ticker/BMOD

http://www.biomoda.com/video.html

[Alphatier]

Und wieder ein neues Patent:

Biomoda Adds to Patent Portfolio

* Press Release
* Source: Biomoda, Inc.
* On Monday July 27, 2009, 9:00 am EDT

*
Buzz up! 0
* Print

*
Companies:
o Biomoda inc.

ALBUQUERQUE, N.M., July 27, 2009 (GLOBE NEWSWIRE) -- Biomoda, Inc. (OTCBB:BMOD - News), an Albuquerque-based early cancer detection medical diagnostics company, has filed a new patent on a quantitative method for reading tissue samples for signs of malignant tumor cells, bringing the company's U.S. patent portfolio to four total patents issued or pending.
Related Quotes
Symbol Price Change
BMOD.OB 0.05 0.00
Chart for BIOMODA INC
{"s" : "bmod.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Biomoda's diagnostic for the early detection of various cancers is based on meso-tetra (4 carboxyphenyl) porphine or TCPP, a patented porphyrin compound that binds to cancer cells and fluoresces red under ultraviolet light. The new patent provides a system for verifying the spectral signature of TCPP optically and measuring the photon emission rate of TCPP labeled cancerous and precancerous cells.

"Until now, TCPP-labeled tissue samples have required the trained eye of a cytopathologist to determine whether there is cancer present," said John Cousins, Biomoda president and chief executive officer. "This system gives us a measurable, quantitative way to make that determination based on a scientific phenomenon, the photon energy emission from each cell."

Biomoda's first product, an in-vitro test for the early detection of lung cancer, is currently in clinical trials. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample that is screened for cancer cells in the Biomoda lab under the protocol described in the new patent.

Titled "System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP)," the patent builds on the science underlying Biomoda's cytology-based diagnostic. Originally developed at Los Alamos National Laboratory and trademarked under the names CyPath(r) and CyDx(r), the TCPP platform is the foundation for several Biomoda product lines and medical tools still in the developmental stage.

Cousins said, "This patent represents a giant step forward in terms of making our cancer diagnostic available to large populations because trained technicians anywhere in the world will be able to process tissue samples accurately and inexpensively."

In addition to the new U.S. patent, Biomoda was recently awarded patents for its proprietary technology in Japan and Australia.

[pennyjoe]

.

Biomoda President Testifies Before New Mexico Legislature

Supporting Clinical Funding for an Early Lung Cancer Detection Study



Santa Fe, N.M., July 28, 2009 -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD), Albuquerque, New Mexico, (http://www.biomoda.com) , testifies Wednesday, July 29th before the New Mexico State Legislature’s Interim Tobacco Settlement Committee to report the progress screening veterans in New Mexico for Lung Cancer using the company’s assay Cypath.

The screening study has enrolled over 500 participants, screened approximately 130, and has identified several cases of early stage lung cancer.

“Members of the Tobacco Settlement Committee are at the forefront of funding essential studies to develop a nationwide screening protocol for lung cancer that ultimately will result in saving millions of lives,” said Cousins. “We look forward to being part of this breakthrough effort and we are thrilled to be helping our veterans in this process. The men and women who served our country deserve the very best healthcare. This screening program is providing just that.”


.

[pennyjoe]

.

es gibt nur 77 mio aktien

wenn biomoda die zulassung von der fda bekommt, wird hier ein feuerwerk abgebrannt

ich bin auf jedenfall drin - ihr auch?

.

[pennyjoe]

.

Biomoda Study Will Screen 500 New Mexico Veterans for Lung Cancer
8/4/2009 8:30:38 AM - GlobeNewswire

SANTA FE, N.M., Aug 4, 2009 (GlobeNewswire via COMTEX News Network) --
Biomoda, Inc. (OTCBB:BMOD), the New Mexico Department of Veterans Services, and the New Mexico Institute of Mining and Technology (NM Tech) appeared before the State Legislature's Interim Tobacco Settlement Committee to report that 500 New Mexico veterans have committed to participate in a state-funded program for the detection of early-stage lung cancer based on Biomoda's proprietary technology.

John Cousins, Biomoda president and CEO, told the legislators that the $1.65 million appropriated for the screening program has raised awareness among New Mexico veterans of the U.S. armed forces about their increased risk for developing lung cancer and the importance of early detection. Of the 500 volunteers for the program, more than 100 have completed the screening.

Biomoda's diagnostic is based on a patented molecular marker originally developed at Los Alamos National Laboratory that preferentially binds to cancerous or aberrant cells and causes them to fluoresce under ultraviolet light. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample to be processed with Biomoda's CyPath(r) assay in the Biomoda lab. Results are compared to a CT scan and PAP stains read by cytopathologists to confirm accuracy.

"This study will help us move the CyPath(r) technology closer to FDA approval and commercialization, bringing a non-invasive, accurate, and inexpensive tool for detecting cancer to market," Cousins said. "The health benefits of the Biomoda diagnostic are obvious and have worldwide implications."

NM Tech presented a scientific abstract on the Biomoda diagnostic at the 13th World Conference on Lung Cancer in San Francisco, CA, on August 2, 2009.

For more information on Biomoda, visit the website at www.biomoda.com. Follow news about Biomoda on Facebook and Twitter.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Biomoda, Inc.

Biomoda, Inc. John Cousins 505.821.0875 [e-mail]

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

[pennyjoe]

.

hier wird in den kommenden monaten geld verdient und nicht nur wegen miss mexico

http://www.biomoda.com/events.htm

der startschuss ist schon gefallen

Price Change % Change Volume Day High/Low 52 Week High/Low
0.07 +0.025 +55.56% 246,038 0.07/0.05 0.08/0.011

.

[pennyjoe]

.

ich hab's euch doch gesagt

von us$ 0,02 auf 0,11 500%

und das ist erst der anfang

http://www.allstocks.com/level2quotesotcbb1.html

.

[pennyjoe]

.

bis 15ct sind noch einpaar pakete zu haben

.

[pennyjoe]

.

nicht vergessen, die waren schon mal bei US$ 3,70

.

[pennyjoe]

.

ja bin ich denn hier alleine investiert?

.

[pennyjoe]

.

und schon stehen wir auf US$ 0,14

100% an einem tag

.

[pennyjoe]

.

scheint so, als ob es news gibt, die zum kauf animieren

ob es insider sind, kann ich nicht herausfinden

bisher:

INSIDER HOLDERS*

Individual/Entity Most Recent Trans. Shares Owned as of Trans. Date
COUSINS JOHN J
Officer Purchase
18-Sep-08 2,800,000
18-Sep-08
DORIAN CONSTANCE
Officer Ownership Statement
1-Jan-09 430,000
1-Jan-09
GERSHIN VERRITY
Officer Ownership Statement
9-Aug-07 532,200
9-Aug-07

.

[pennyjoe]

.

mittlerweile haben wir die US$ 0,15 und ca 300.000 umsatz

nicht vergessen es gibt nur 77 mio aktien

der echte run kommt noch

ist natürlich nur meine persönliche meinung und soll niemanden zum kauf oder verkauf dieser aktie verführen

.

[pennyjoe]

.

was sag ich - wir sind bei US$ 0,17

und im ask gibt es nur noch welche zu 0,20

.

[pennyjoe]

.

nur heute + 142%

.

[pennyjoe]

.

ups jetzt gibt es nur noch welche zu US$ 0,295

.

[pennyjoe]

.

ganz kurz waren wir schon bei US$ 0,28

wahnsinn - durchmarsch von 0,07

.

[pennyjoe]

.

nur schade, dass ich hier alleinunterhalter bin

.

[Alphatier]

Antwort auf Beitrag Nr.: 37.735.664 von pennyjoe am 07.08.09 20:03:11

Ne ne

einer ist schon noch da: Ich glaub an die Firma seit 3 Jahren - waren ja schon mal bei über 3 Dollar.

Was da heute passiert ist, kann ich mir leider nicht erklären (ist aber nicht schlecht )

[pennyjoe]

.

ich vermute den grund für den rasanten kursanstieg hier:

Albuquerque, NM (June 15, 2009) – The New Mexico Institute of Mining and Technology (NM Tech) will present data from Biomoda, Inc. (OTCBB : BMOD) on its non-invasive, inexpensive and accurate diagnostic test for the early detection of lung cancer at the 13th World Conference on Lung Cancer in San Francisco, CA, July 31 to August 4, 2009.

investoren sind aufmerksam geworden, haben 2 - 3 tage recherschiert und steigen jetzt ein, weil sie die extreme unterbewertung erkannt haben.

da werden noch einige auf den zug aufspringen, schließlich fährt er gerade erts an

.

[pennyjoe]

.

diese woche kann es noch einmal richtig spannend werden

es kommt darauf an, ob anschlusskäufe der neuen investoren stattfinden

also haltet euch schön fest - we are ready to rumble

.

[ringo240]

Antwort auf Beitrag Nr.: 37.745.394 von pennyjoe am 10.08.09 15:20:03

hallo pennyjoe...
ich verfolge die BMOD weil ich einige Kunden habe, die darin investiert (allerdings nicht sehr glücklich darüber) sind.
Bin gespannt, ob die je wieder da rauskommen.

[Alphatier]

Antwort auf Beitrag Nr.: 37.755.314 von ringo240 am 11.08.09 16:18:50

Wer auf Kurse von 1 US$ und mehr hofft, wird viel Geduld brauchen.
Ein erneutes FDA-Approval kann erst aufgrund vollständiger klinischer Daten erfolgen.

Für mich sind schon 20 Cent ein satter Vervielfacher

Sollte jedoch eine erneute Zulassung der Diagnostik durch die FDA erfolgen, geht Biomoda ab wie ne Rakete (wenn sie nicht zuvor schon von einem Großen geschluckt wurden).

[ringo240]

Antwort auf Beitrag Nr.: 37.759.152 von Alphatier am 11.08.09 23:57:30

Haben Sie Aktien über die "Börse" gekauft... und damit ohne Sperrvermerkt, oder auch, so wie meine Kunden, über Vermittler mit Sperrvermerk, der nur schwer zu löschen ist ???

sagt Ihnen China Voice was? oder Biodiesel ?
Danke für Input

[pennyjoe]

.

so - habe meine bio mit gewinn verkauft - steuerfrei

allen investierten noch viel erfolg

.

[Alphatier]

Antwort auf Beitrag Nr.: 37.828.734 von pennyjoe am 21.08.09 18:20:42

Wie konntest Du nur ?

Heute +80% und es geht weiter, wenn FDA durchgeht.

[Alphatier]

Antwort auf Beitrag Nr.: 37.760.765 von ringo240 am 12.08.09 10:23:08

Von ChinaVoice und Biodiesel hab ich gehört - aber die Finger gelassen.

Meine Aktien waren "eingeschränkt" (ums vorsichtig zu formulieren). Wie das dann geht mit Traden solcher Stücke etc. geb ich nicht in einem öffentlichn Forum preis - wäre ein juristische Rat, sorry.

[Alphatier]

Antwort auf Beitrag Nr.: 37.760.765 von ringo240 am 12.08.09 10:23:08

Hallo ringo240,

ich darf zwar keine Tipps geben, hier aber ein vielleicht hilfreicher Link:

http://www.regulation-s.com/regulation-s-stages-fees/regulat…

[Alphatier]

Antwort auf Beitrag Nr.: 37.760.765 von ringo240 am 12.08.09 10:23:08

Und noch ein Link, den man als Professioneller (mit Kunden) eigentlich kennen sollte (ist immerhin bei der SEC):

http://www.sec.gov/investor/pubs/rule144.htm

[Alphatier]

Letzte Unternehmensmeldung, die vielleicht den Kursprung erklärt - mehr ist nicht zu erfahren im Moment:

We have recruited over 500 participants so far, and have screened 120. We have full results for the first 40 and they are being analyzed and correlated. It is too early to be definitive, but early results look strong.

[Bennono]

ich habe vor einiger Zeit über die First Financial Management biomoda-Aktien gekauft. Wer weiß etwas über First Financial, exsistiert dieses Unternehmen überhaupt noch? Ich erreiche immer nur den Anrufbeantworter, der versprochene Rückruf bleibt aus.

Wer kann mir sagen, wie Biomodaaktien an der OTC verkauft werden können.

[Alphatier]

Antwort auf Beitrag Nr.: 37.935.557 von Bennono am 08.09.09 09:24:21

Hallo,

hab hier zwar bereits zwei wichtige Links hinterlegt.

Hier aber nochmal einer - die sollten Dir helfen können, falls Deine Aktien gem. Regulation S gesperrt sind:

http://www.regulation-s.com/regulation-s-stages-fees/regulat…

[Alphatier]

Schon wieder News (die sind richtig fleißig)


Biomoda Clinical Trial Adds Longitudinal Study to Protocol

ALBUQUERQUE, N.M., Sept. 14, 2009 (GLOBE NEWSWIRE) -- Biomoda, Inc.'s (OTCBB:BMOD - News) (www.biomoda.com) Phase II clinical trial to screen military veterans for early-stage lung cancer has been enhanced to include a longitudinal component, which will provide additional data on the efficacy of the Biomoda diagnostic.

"Study participants whose initial results indicated areas of concern -- the presence of nodules on the lungs or a positive read for cancer cells -- have been asked to return for follow-up screening," commented John J. Cousins, President and Chief Executive Officer of Biomoda, Inc. "The ability to monitor study participants over the long term will no doubt result in a better medical outcome for them as well as provide invaluable data for Biomoda as we prepare for Phase III pivotal trials and FDA approval."

The Biomoda diagnostic, trademarked under the name CyPath(R), is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. The original protocol for ongoing clinical trials focused on the use of the assay as a diagnostic.

"Staying in contact with study participants and monitoring their lung health will help us expand the utility of the CyPath(R) assay beyond early diagnosis to actually measuring the success of treatment," Cousins said. "We will eventually be able to tell patients how effectively their therapy is targeting their cancer."

Biomoda's Phase II clinical trial is being conducted in partnership with the New Mexico Department of Veterans Services (NMDVS) and the New Mexico Institute of Mining and Technology (NM Tech). To date, more than 500 military veterans have enrolled in the program. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample which is screened for cancer cells with both the CyPath(R) assay and traditional Pap staining. Participants also undergo a computed tomography (CT) scan.

The current study will be expanded to include up to 3,500 patients for the Phase III pivotal clinical trial. Biomoda expects results from these studies to be sufficient for FDA approval by 2011.

Based in Albuquerque, New Mexico, Biomoda, Inc. is a cancer diagnostics company focused on the development of accurate, inexpensive, and noninvasive in-vitro tests for the early detection of cancer.

For more information on Biomoda, check the website at www.biomoda.com and follow Biomoda on Facebook and Twitter.

[Alphatier]

Und schon wieder Neuigkeiten:


Biomoda Updates New Mexico Legislature on Screening Program for New Mexico Veterans

ALBUQUERQUE, N.M., Sept. 21, 2009 (GLOBE NEWSWIRE) -- In an update to New Mexico state legislators, Biomoda, Inc. (OTCBB:BMOD - News) President John Cousins reported that the state-funded lung cancer screening program for military veterans has recruited 500 participants, completed the screening process on 130 participants and is proceeding on schedule with an ancillary benefit.

"Our focus, of course, is early detection of asymptomatic lung cancer; however, as a result of the comprehensive protocol for this study we have also detected potentially life-threatening conditions, including emphysema, pneumonia and coronary artery disease, in approximately 80 percent of our participants and referred them to follow-on medical care," Cousins said.

The Legislature has appropriated $1.65 million to date to screen New Mexico veterans for early-stage lung cancer using Biomoda's proprietary diagnostic. Testifying before the Military and Veterans' Affairs Committee of the New Mexico State Legislature, Cousins said that Biomoda expects the pilot program to identify five to ten individuals with early-stage lung cancer by the end 2009.

Biomoda is conducting the screening study in collaboration with the New Mexico Department of Veterans Services (NMDVS) and the New Mexico Institute of Mining and Technology (NM Tech).

Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample to be processed with Biomoda's patented CyPath(R) assay in the Biomoda lab. Biomoda's CyPath(R) results are compared to a CT scan and a traditional cytopathology analysis of the sputum sample to confirm accuracy. CyPath(R) is based on a process utilizing a molecular marker, originally developed at Los Alamos National Laboratory that preferentially binds to cancer cells and fluoresces red under ultraviolet light.

For more information on Biomoda, visit the website at www.biomoda.com. Follow news about Biomoda on Facebook and Twitter.

[Alphatier]

Biomoda Engages Renowned Researcher to Lead Longitudinal Component of Lung Cancer Study

ALBUQUERQUE, N.M., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Biomoda, Inc. (OTCBB:BMOD - News), a diagnostics company focused on the development of accurate, inexpensive, and noninvasive in-vitro tests for the early detection of cancer, announced Dr. Thomas Bauer will read the follow-up CT scans and other data on study participants as part of the longitudinal component of the research of the Phase II clinical trial of its assay. Dr. Bauer is the Principal Investigator (PI) overseeing the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer.

"Dr. Bauer's work on our study is a significant step toward proving the usefulness of the CyPath(R) assay as an early screening tool for lung and other cancers," Biomoda President John Cousins said. "Repeat screenings under the longitudinal part of the study will probably save lives in our study cohort as well as provide additional data critical to FDA approval of the assay."

Dr. Bauer is chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, in Delaware as well as clinical assistant professor of surgery at Jefferson Medical College and adjunct assistant professor of biological sciences at the University of Delaware. He has led several lung and esophageal cancer studies and heads up Christiana's participation in the International Early Lung Cancer Action Program (I-ELCAP).

I-ELCAP is a group of 52 institutions in nine countries dedicated to advancing the knowledge base for early detection and treatment of lung cancer. Dr. Bauer's work with Biomoda follows the I-ELCAP Enrollment and Screening Protocol updated and published on Feb. 10, 2009.

"In addition to his thoracic surgery practice and his faculty positions, Dr. Bauer is widely recognized by his peers as one of the top lung cancer researchers in the field. We are extraordinarily lucky to have his expertise and experience on our study," Cousins said.

The Biomoda diagnostic, trademarked under the name CyPath(R), is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample that is screened for cancer cells with both the CyPath(R) assay and traditional Pap staining. Participants also undergo a CT scan.

[Alphatier]

Das ist mal ne nette Meldung:

http://www.biomoda.com/statefair.htm

[Alphatier]

Jetzt gehts langsam los: Ab Phase III wirds erst richtig interessant (danach käme die Zulassung - im Erfolgsfall). Leider scheint sich außer mir keiner für diesen Multimillionenmarkt zu interessieren (aber auch egal).


Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study

ALBUQUERQUE, N.M., Oct. 23 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD - News), a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer. The next stage of the Phase II trial calls for Biomoda to begin testing samples from already-diagnosed lung cancer patients in accordance with the study protocol approved by the U.S. Food and Drug Administration (FDA).

"More than 500 veterans volunteered to be screened with the Biomoda assay. It has been heartening to see so many men and women who served their country in the armed forces willing to help once again by participating in this important study," said John Cousins, President of Biomoda. "The study is not complete, but we are pleased with the progress to date and expect to have final data in the first half of 2010."

The Biomoda diagnostic, trademarked under the name CyPath®, is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample that is screened for cancer cells with both the CyPath® assay and traditional Pap staining. Participants also undergo a CT scan.

Dr. Thomas Bauer, chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, in Delaware, is the Principal Investigator overseeing the Phase II clinical trial. He has lead several lung and esophageal cancer studies and heads up Christiana's participation in the International Early Lung Cancer Action Program (I-ELCAP).

[pennyjoe]

.

biomoda hat ne neue sekretärin


Biomoda Board of Directors Names New Corporate Secretary


2009-10-27 08:30 ET - News Release





ALBUQUERQUE, N.M., Oct. 27 /PRNewswire-FirstCall/ -- The Board of Directors of Biomoda, Inc. , (www.biomoda.com) an early cancer detection medical diagnostics company, has elected Maria Zannes to serve as Corporate Secretary. Zannes originally joined the Biomoda Board May 1, 2008.


"Maria's extraordinary background in corporate and legal affairs makes her the perfect individual to safeguard our commitment to good corporate governance," said John Cousins, Biomoda president and chief executive officer. "As we progress through clinical trials with the Biomoda diagnostic, Maria's expertise will keep us focused on best practices and regulatory compliance."


Zannes replaces Verrity Gershin in the post. "The board wants to acknowledge Verrity's commitment to Biomoda and her work with the company over the years. We're pleased that she will continue to serve as office manager and provide the critical support necessary to get our lifesaving technology to the marketplace," Cousins said.


Zannes brings more than 30 years of experience in the environmental and energy industries where she worked in multiple capacities, including federal lobbyist and company president. Formerly president of a national waste-to-energy trade group in Washington, D.C., Zannes currently consults for private clients in the medical, energy, and environmental industries. She is a research associate for Columbia University's Earth Engineering Center and a member of the Board of Directors of American Homecoming Foundation, a non-profit organization focused on providing assistance to homeless veterans. She was a legislative aide and press secretary to U.S. Rep. Charles Wilson (D-Texas). Zannes is licensed to practice law in Washington State and New Mexico.


Biomoda's first product, an in-vitro test for the early detection of lung cancer trademarked as CyPath(R), is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. Originally developed at Los Alamos National Laboratory, the molecular marker technology is the foundation for several Biomoda product lines and medical tools still in the developmental stage.




Biomoda, Inc.

[Alphatier]

Antwort auf Beitrag Nr.: 38.262.424 von pennyjoe am 27.10.09 16:01:27

Die haben wenigstens eines begriffen:
Lieber ne unwichtige News als gar keine

[Alphatier]

Hier mal ne wirklich wichtige News - denn jetzt wirds heiß:


Biomoda Prepares for Phase III Clinical Trials


ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Medical diagnostics company Biomoda, Inc. (OTCBB: BMOD - News) is taking preliminary steps to launch multisite Phase III clinical trials of its in-vitro diagnostic for early-stage lung cancer, trademarked under the name CyPath®.

“As the Phase II trial wraps up, we are making sure that all the pieces are in place to move immediately to a nationwide Phase III,” Biomoda President John Cousins said. “Most significantly, Dr. Thomas Bauer, the Principal Investigator (PI) overseeing Phase II, has agreed to continue in the same role for our Phase III trials. Dr. Bauer is widely recognized as one of the top lung cancer researchers in the field, and we are privileged to be working with him.”

Bauer, chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, and head of Christiana’s participation in the International Early Lung Cancer Action Program (I-ELCAP), is coordinating site selection for the final phase of testing on the CyPath® assay. Bauer’s work with Biomoda follows the I-ELCAP Enrollment and Screening Protocol, and all sites selected for the Phase III trials will be I-ELCAP approved.

Cousins said that Biomoda is finalizing the protocol for its Phase III trials for submission to an Institutional Review Board (IRB) in early 2010. IRB review protects research subjects by making sure the study protocol adheres to U.S. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services regulations, that risks to participants are minimized and acceptable in light of the possible benefits, that the informed consent document is accurate, and that the research is conducted in an ethical manner.

Biomoda is seeking FDA approval of its cytology-based screening technology as a Class III medical device under the Pre-Market Approval (PMA) process. “When Phase II results are complete, probably by the end of January 2010, we will report them immediately to the FDA along with the pre-IDE (Investigational Device Exemption) filing,” Cousins said. “Based on feedback from the FDA to date, we anticipate no delays in moving forward with Phase III.”

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. The CyPath® assay is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light.

[Alphatier]

Biomoda ist einfach nur fleißig - neues Patent erteilt:

Biomoda Awarded New Patent

Biomoda’s Patent Portfolio Continues to Expand

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Biomoda, Inc. (OTCBB: BMOD - News), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda’s screening assay for the early detection of cancer.

The U.S. Patent entitled “Method for Making 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) Solution and Composition Comprising TCPP,” describes the new formulation of the Biomoda assay trademarked under the name CyPath®.

“This patent basically gives Biomoda a lock on the ‘recipe’ for the TCPP Labeling Solution," said Biomoda President John Cousins. "Our formulation moves beyond the original work done on TCPP at Los Alamos National Laboratory and incorporates the cutting-edge science we are doing in our own lab.”

TCPP is the foundation for several Biomoda product lines and medical diagnostics. The company’s first product, an in-vitro test for the detection of early-stage lung cancer, is currently in Phase II clinical trials. Study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath® assay in the Biomoda lab. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm accuracy.

Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Multi-site Phase III trials, the final step before FDA approval, are scheduled to begin in early 2010.

In addition to U.S. patents (6,838,248 and 7,384,764), Biomoda also holds patents for its proprietary technology in several foreign countries.

[pennyjoe]

.

gibt es news?

0,26 und 320.000 umsatz

.

[Alphatier]

Antwort auf Beitrag Nr.: 38.824.910 von pennyjoe am 27.01.10 18:06:14

Sind schon 525.000 Umsatz zu 0,25

denke das liegt an der Präsentation in San Franzisko:
s. Webpage www.biomoda.com

[Alphatier]

Umsatz über 800.000 Stck. heute

Da ist was im Busch

[Alphatier]

Wichtige News:

LOS ANGELES, CA--(Marketwire - 01/28/10) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that New Mexico-based cancer diagnostics company Biomoda (OTC.BB:BMOD - News), whose early cancer detection assay came from a spin-off of the Los Alamos National Labs, is on the verge of completing its Phase II studies for lung cancer patients.

The end of these studies will mark another important milestone for the company since upon completion they plan to submit Phase II data to European regulators in hopes of being granted a CE Mark. If successful, it would open the door for the company to begin commercializing the product throughout Europe by the middle of this year. The market potential for the assay is more than twice as large as it is in North America.

With an estimated 90 million smokers in the U.S., and 215 million in Europe, health officials say there is a serious need for advanced, early detection lung cancer diagnostics technology.

The company plans also to begin Phase III trials at multiple locations throughout the U.S. later this year. In time, it also plans to test and commercialize an entire portfolio of early cancer diagnostics tools, based on the same technology, for deadly breast, oral, prostate, bladder, colorectal, and cervical cancers.

All of these pending developments present opportunities for a significant capital appreciation in the stock price and expected positive Phase II results will certainly re-rate the stock.

A complete report about the company, complete with a video interview of its CEO, John Cousins, is available now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/26581-biomoda…

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies. See our complete disclosure statements at BioMedReports.

[Alphatier]

Nachdem ich hier schon mal gefragt wurde, wie man denn Biomoda-Shares, die "restricted" sind, entsperren und damit frei handelbar machen kann, hier die Antwort des Biomoda-Transferagenten:

In regards to removing a restriction from your shares of Biomoda, Inc. stock, the following is required:

1. Letter of Instruction, stating what you wish to be done.
2. Original stock certificate
3. $45.00 USD transfer fee, made payable to OTR, Inc.
4. Legal Opinion Letter. This can be acquired through a securities attorney, or websites such as www.144opinions.com.

Please note that Biomoda does not provide legal opinions.

Die Kontaktperson des Transferagenten, Jessica DeNoto, erreicht man per Mail - so gibts zumindest Biomoda weiter:

[e-mail]

[Alphatier]

News:

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--John Cousins, president of cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD - News) (www.biomoda.com), has been elected to the Board of Directors of the New Mexico Biotechnology and Biomedical Association (NMBio).

“I know firsthand how receptive New Mexico is to the bioscience industry,” Cousins said. “NMBio plays a critical role in promoting our industry and our region by providing a platform for interaction between the science side and the business side of biotech.”

NMBio was established to provide a forum for information exchange in the life sciences, develop initiatives to enhance small business success, provide education and outreach, help establish collaborations, and publicize the New Mexico bioscience industry. NMBio is an affiliate of the national Biotechnology Industry Organization.

As a member of the NMBio Board of Directors, Cousins joins a volunteer group of scientists, academics and other professionals dedicated to the advancement of bioscience in New Mexico and the promotion of New Mexico’s capabilities internationally. During his two-year term, Cousins will be involved in NMBio-sponsored programs and events, policy development and a variety of committee assignments.

“Biomoda has benefited from our affiliation with NMBio and I look forward to building the biotech community in New Mexico by helping other companies in the bioscience sector succeed,” Cousins said.

Biomoda’s initial product is a diagnostic assay for the detection of early-stage lung cancer. Currently in Phase II clinical trials, the CyPath® assay is a porphyrin-based compound that preferentially binds to cancer cells and causes them to fluoresce red under ultraviolet light. CyPath® is for investigational use only pending approval by the U.S. Food and Drug Administration (FDA).

[Alphatier]

Analysteneinschätzung :

Biomoda: Undervalued Cancer Diagnostics Company with Important Pending Developments (OTCBB:BMOD)
Written by Mike Rabe

Here I present a largely undiscovered cancer diagnostics biotech company that I believe will help you soundly beat the market in 2010. The company is Biomoda, Inc., a fully reporting over the counter stock with pending key developments trading under the ticker symbol BMOD.

Biomoda is an Albuquerque, New Mexico-based cancer diagnostics company. Their mission is to save lives by making the early diagnosis of the deadliest cancers available at an affordable cost to large populations worldwide.

The company's early cancer detection assay came from a spin-off of the Los Alamos National Labs through a licensing and cooperative development agreement. The company then licensed the the original patents and now has their own patent portfolio which they plan to expand into early detection assays for multiple cancer detection applications.

Biomoda’s Cypath® diagnostics technology is approximately two weeks from completing its Phase II studies for lung cancer patients.

Company CEO, John Cousins tells BioMedReports that early data from the studies shows that primary endpoints in the "high risk" group have been exceeded. Now, researchers are gathering comparison data for their "positive controls." The seek to find statistical significance showing a minimum of at leat 80% accuracy in the technology's readings.

The end of these Phase II studies will mark another important milestone for the company since they will be able to submit the completed Phase II data to European regulators in hopes of being granted a CE Mark. If successful, it would certify that Biomoda’s Cypath® has met EU consumer safety and health requirements and open the door for the company to begin commercializing the product throughout Europe by the middle of this year. The market potential for the assay is more than twice as large as it is in North America.

With an estimated 90 million smokers in the U.S., and 215 million in Europe, health officials say there is a serious need for advanced, early detection lung cancer diagnostics technology.

Since lung cancer continues to be the leading cause of cancer death in the U.S, the company will simultaneously begin Phase III trials at multiple locations throughout the U.S. After those trials conclude, it hopes to submit an application for approval to the FDA as a Class III PMA IVO device. Decisions for such devices are usually given within 9 months.

Interestingly, the Phase II studies were not funded at stock holders' expense, but by the New Mexico State Legislature from the state’s tobacco settlement funds. Biomoda recruited at-risk military veterans for the trials and the program was screened and administered by the New Mexico Department of Veterans Services (NMDVS) and the New Mexico Institute of Mining and Technology (NM Tech).

Biomoda’s technology platform is based on Tetrakis Carboxy Phenyl Porphine (TCPP), which is a porphyrin that binds to cancer cells. Porphyrins are naturally occurring pigments that fluoresce red when exposed to UV light. This creates a very accurate diagnostics test. The technology is scalable and easy to automate. This means large populations can be screened at affordable costs.
Biomoda also plans to test and commercialize an entire portfolio of early cancer diagnostics diagnostics tools, based on the same technology, for deadly breast, oral, prostate, bladder, colorectal, and cervical cancers.

Biomoda’s stock (OTC:BMOD) is currently undervalued, but all of these pending developments present opportunities for a significant capital appreciation in the stock price. Excellent Phase II results will certainly re-rate the stock.

Investors have the stock trading higher in anticipation of these upcoming milestones, but the share float is very tight and a breakout beyond the previous 52-week high of $.37 could signal a strong push upward.

[Alphatier]

Tolle News :

Biomoda and Amigenics Announce Collaboration

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Biomoda, Inc. (OTCBB: BMOD - News) (www.biomoda.com) and Advanced Medical Imaging and Genetics (Amigenics) (www.amigenics.com), an innovative medical clinic specializing in prevention and early detection of disease, announced their intent to collaborate on a variety of projects to advance technology for the early detection of lung and other cancer.

“Amigenics is at the forefront of individualized health care using state-of-the-art imaging and diagnosis,” said John Cousins, President of Biomoda. “We are excited about the prospect of collaborating with them and strengthening both companies.”

Amigenics’ staff of physicians and genetic counselors offer personalized disease risk screening, clinical evaluations, genetic counseling and treatment plans for a variety of conditions that affect adults. Amigenics’ Las Vegas, Nevada, clinic combines comprehensive medical evaluations with the revolutionary technologies of advanced medical imaging and genetics.

Cousins said the two companies will pursue initiatives that complement their businesses. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Multi-site Phase III trials, the final step before FDA approval, are scheduled to begin in 2010.

“I anticipate that our Phase III trials will incorporate a variety of advancements in the methods of collection, data correlation, and imaging due to our collaboration with Amigenics,” said Cousins. “We always are looking to partner with companies leading the pack, and Amigenics certainly is a leader.”

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

[pennyjoe]

.


Biomoda and Obio Form Strategic Alliance to Expand Lung Cancer Screening Program


2010-03-10 08:35 ET - News Release


ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) and Obio, Inc., a corporation formed to pursue public and private funding for cancer research in Ohio, are working together to expand Biomoda’s lung cancer screening program for veterans into Ohio.

“A strategic alliance with Obio gives Biomoda a presence in a state that is recognized as a leader in cancer research and treatment. Ohio’s leaders have established programs and funding to attract promising biomedical technologies to the state through innovative public initiatives that support both research and commercialization,” said John Cousins, President of Biomoda.

Biomoda currently is conducting clinical trials of its CyPath® lung cancer diagnostic assay, an inexpensive, noninvasive test designed to identify early-stage lung cancer by binding to cancer cells and causing them to fluoresce under ultraviolet light. Phase II trials have focused on military veterans who are at least 25 percent more likely to develop lung cancer and die from the disease.

Cousins said that Obio will help Biomoda launch a veterans screening program in Ohio, similar to ones completed in New Mexico and under consideration by the Nebraska Legislature. “We are also identifying sites for the upcoming Phase III trials, and Ohio is home to several world-class comprehensive cancer centers.”

Biomoda is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. CyPath® is currently for investigational use only.

.

[Alphatier]

Antwort auf Beitrag Nr.: 39.104.417 von pennyjoe am 10.03.10 15:08:47

Tolle News

Die sind richtig fleißig - jetzt sollte bloß noch der Kurs dahin, wo er hingehört

[Alphatier]

Biomoda Announces up to $2.0 Million Private Placement

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD - News) (www.biomoda.com) today announced that it has entered into agreements with a syndicate of institutional investors for up to $2.0 million. LifeTech Capital, a division of Aurora Capital LLC, acted as the exclusive placement agent for the financing.

“We are extremely pleased with the outcome of this round of financing,” said John Cousins, Biomoda president and chief executive officer. “The institutions that participated in this investment speak volumes about the promise of our technology and the validity of our business model and strategy. This is a significant stamp of approval from prestigious investment funds with a strong history of success in the biotech sector.”

Biomoda’s CyPath® diagnostic assay which binds to cancer cells and causes them to fluoresce red under ultraviolet light is currently in clinical trials as a diagnostic for early-stage lung cancer. Pending U.S. Food and Drug Administration (FDA) clearance, CyPath® is for investigational use only.

“Proceeds from this financing will allow us to continue our clinical trials, submit our findings to the FDA for clearance as a Class III medical device and begin commercialization of a breakthrough technology for the early detection of cancer,” Cousins said. The initial funding is $1,000,000, with the investors having the right to invest an additional $1,000,000.

Cousins praised LifeTech Capital, (www.lifetechcapital.com) a division of Aurora Capital LLC, (www.auroracapital.com) for bringing the transaction to a successful close. “The investment banking team at LifeTech specializes in the unique needs of the biotech and medical technology industries. They understand how to analyze the future value of technologies like ours and match companies with the right investors,” Cousins said.

The securities described above were sold by the Company in private placements and were not registered under the Securities Act of 1933, as amended (the "Securities Act"). The securities were sold in reliance upon exemptions from the registration requirements of the Securities Act pursuant to Regulation D promulgated under the Securities Act. Therefore, the securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and any applicable state securities laws. This press release does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities.

[pennyjoe]

.

ist ja wunderbar, dass biomoda sich geld besorgt

1 mio und wenn sie brauchen eine zweite

aber zu welchem preis steht nicht drin

.

[Alphatier]

Antwort auf Beitrag Nr.: 39.169.444 von pennyjoe am 18.03.10 15:36:05

Zumindest glauben Fondsgesellschaften an das Unternehmen - und die Aktien sind gesperrt und damit nicht handelbar, Auf weiteres also keine Verwässerung.

Man darf gespannt sein.

[Alphatier]

Und sie steigen ... und steigen ... und .......

[pennyjoe]

.

und steigen ........ und ......... ich bin nicht dabeieieiei.......

.

[Alphatier]

... und steigen.

[johnlawat]

neue website: www.biomoda.com

[Alphatier]

Antwort auf Beitrag Nr.: 39.231.423 von johnlawat am 28.03.10 13:45:50

Schön geworden - wurde auch Zeit

[Alphatier]

... und steigen

34er-Marke erreicht.

Da ist was im Busch. Hoff ich.

[Alphatier]

Und wieder gestiegen ...

Kommt dieses Jahr noch 1US$ ?

[pennyjoe]

.

einen spread in der größenordnung hab' ich selten gesehen


bid ask spread
0,15 0,52 71,15%

vielleicht sollte ich eine testorder mit 0,16 reingeben

.

[pennyjoe]

.

minus 33% ist aber heftig

.

[Alphatier]

Antwort auf Beitrag Nr.: 39.256.316 von pennyjoe am 31.03.10 17:28:13

Ist halt ein Zockerpapier - fürs Erste. Hat sich wohl rumgesprochen.

Nun fast schon wieder Einstiegskurs - aber nicht zu 0,16 (da halten schon Andere den Daumen drauf, vor allem bei über 500T umgesetzten Stücken)

[pennyjoe]

.

heute nochmal minus 20% - einfach klasse, denn ich bin wieder mit im boot zu us$ 0,23

.

[Alphatier]

Antwort auf Beitrag Nr.: 39.265.206 von pennyjoe am 01.04.10 18:14:05

Na dann
toi toi toi

[pennyjoe]

.

aktuell neutral

aber das 6-monatsziel ist ok

http://www.allotcbb.com/quote.php?symbol=BMOD

.

[pennyjoe]

.

das kursziel finde ich ok


LifeTech Capital Initiates Research Coverage of Biomoda


2010-05-04 09:20 ET - News Release


ALBUQUERQUE, N.M. -- (Business Wire)

Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com), a cancer diagnostics company, is pleased to announce that LifeTech Capital, a division of Aurora Capital LLC, has initiated independent research coverage on Biomoda with a “Strong Speculative Buy” recommendation and a 12- to 18-month price target of $1.00 per share. The report, which was authored by Stephen M. Dunn, Senior Managing Director, Research and William D. Dawson, Senior Vice President, Research for LifeTech Capital, is available online at www.lifetechcapital.com/reports.htm.

LifeTech Capital is an investment bank that specializes in the biotechnology and medical technology industries. Biomoda does not endorse the reports, projections or statements of any analyst.

.

[pennyjoe]

.


BIOMODA INC
Symbol BMOD



Biomoda and Obio Sign MOU to Expand Lung Cancer Screening Program


2010-06-02 07:10 ET - News Release


ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) and Obio, a corporation formed to pursue public and private funding for cancer research in Ohio, signed a memorandum of understanding (MOU) to establish a CLIA-certified Biomoda clinical laboratory in Ohio to support ongoing research and development on Biomoda’s porphyrin-based assay for the detection of early-stage cancer.

The Clinical Laboratory Improvement Amendments (CLIA) were passed by Congress in 1988 to establish standards for laboratory testing and ensure the accuracy and reliability of patient test results. Laboratories that meet CLIA standards are certified by the U.S. Department of Health and Human Services.

“We are ready to expand our strategic alliance with Obio to include operational facilities that will put us in closer contact with Ohio’s top-rated medical, scientific and technical resources,” said Biomoda President John Cousins. “Ohio is proactively attracting promising biotech companies to the state through public initiatives that support research and commercialization. This fits perfectly with our strategic plan for taking CyPath® into the marketplace.”

Biomoda currently is conducting clinical trials of its CyPath® labeling solution, an inexpensive, noninvasive assay designed to identify early-stage lung cancer by binding to cancer cells and causing them to fluoresce under ultraviolet light. Biomoda is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. CyPath® is currently for investigational use only.

Initially, the lab formed in partnership between Biomoda and Obio could employ up to 12 trained technicians to prepare fluid and tissue samples for immersion into the CyPath® labeling solution and subsequent screening under an ultraviolet microscope. Pending FDA approval, widespread commercialization of the CyPath® product would require significant expansion of the lab facility, creating additional jobs and a positive impact on Ohio’s economy.


.

[Alphatier]

Interessanter Bericht:

http://www.lifetechcapital.com/reports/BMOD%20Initiation%200…

[pennyjoe]

.

es geht voran:


Biomoda Awarded Patent in Mexico


2010-06-07 07:10 ET - News Release


ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

Issued by the Instituto Mexicano de la Propiedad Industrial (IMPI), Mexican patent #269352, “Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,” is similar to Biomoda’s U.S. patent 6,838,248, which was issued in 2005. Foreign equivalents are now effective in Mexico, Japan and Australia and are pending in Europe and Canada.

“This patent represents another step in protecting our intellectual property rights internationally,” said Biomoda President John Cousins. "We are strategically building our IP portfolio with an eye on the eventual commercialization and marketing of our CyPath® diagnostic assay to address the global issue of lung cancer mortality.”

The 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine, or TCPP, is the foundation for several Biomoda product lines and medical diagnostics. The company is concluding Phase II clinical trials of its first product, an in-vitro test for the detection of early-stage lung cancer, in which study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath® assay. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm accuracy.

Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only.

Based, in Albuquerque, N.M., Biomoda is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

.

[Alphatier]

Der nächste Milestone ist erreicht:

Biomoda Completes Patient Enrollment and Sample Collection in Pilot Study

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD - News) (www.biomoda.com) today announced it completed patient enrollment and sample collection in a pilot study to determine the clinical sensitivity and specificity of its CyPath® labeling solution for the early detection of lung cancer. Top-line data and results will be released when available.

Biomoda is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. In addition to FDA approval, Biomoda President John Cousins said the company is pursuing a CE Mark to commercialize CyPath® in Europe. CyPath® is currently for investigational use only.

“This is a significant milestone for our CyPath® diagnostic test,” Cousins said. “Now that enrollment and collection are complete, the study team is evaluating data in preparation for publishing results when analysis is complete. We expect the results from this single-blind, non-randomized clinical trial to lead to the launch of the Phase III pivotal trial.”

The Principal Investigator overseeing the CyPath® study is Dr. Thomas Bauer, chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, in Delaware as well as associate professor of surgery at Jefferson Medical College and adjunct assistant professor of biological sciences at the University of Delaware.

The protocol approved for the Phase II pilot study includes two cohorts: a larger group of patients who represent a high-risk population of heavy smokers and a smaller group of patients who had been diagnosed with lung cancer but had not yet begun treatment for the disease. The first cohort was recruited among male and female veterans of the armed services who are known to be at higher risk for developing lung cancer than the general population.

[bvasel]

eine intressante Aktie... leider kann ich sie nicht finden... ich benütze Swissquote und Postfinance... mit Symbol/ISIN/Name/Local-ID habe ich gesucht... kann mir jemand helfen?

[Alphatier]

Antwort auf Beitrag Nr.: 39.744.345 von bvasel am 28.06.10 10:01:27

Die Aktie wird nur in USA gehandelt - am besten über Yahoo finance http://finance.yahoo.com/q?s=BMOD.OB rein oder
http://www.finanzen.net/aktien/Biomoda-Aktie

Kürzel: bmod.ob
WKN: A0MSTL
ISIN: US0906271004

[bvasel]

um was geht es genau bei dieser Aktie? kann mir das jemand erklären (mein englisch Kenntnisse sind überschaubar)

[Alphatier]

Antwort auf Beitrag Nr.: 39.757.061 von bvasel am 30.06.10 13:29:37

Die haben eine Methode entwickelt zur Frühdiagnose von Lungenkrebs - ist patentiert und um einiges günstiger in der Anwendung als herkömmliche Diganosemethoden. Könnte man pribzipiell in der Apotheke kaufen.

[pennyjoe]

.


Biomoda to Participate in OneMedPlace New York Finance Forum


2010-06-29 12:16 ET - News Release


ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) will present on its proprietary CyPath® diagnostic assay for the detection of early-stage cancers at OneMedPlace’s mid-year finance forum in New York on Wednesday, June 30, 2010.

The OneMedPlace conference will connect 75 private and microcap companies with European and U.S. institutional investor groups interested in the healthcare and biotechnology sectors. The focus in New York will be on accessing new sources of capital.

“The OneMedPlace forum gives us an opportunity to introduce our technology to an audience that understands the global market potential for a non-invasive, inexpensive, accurate screening diagnostic assay for cancer,” Biomoda President John Cousins said. “Lung cancer is our first target because it’s the deadliest cancer worldwide and hard to diagnose in the early stages, but we are currently taking a look at expanding our studies to cervical and breast cancer.”

Cousins’ presentation will be Webcast at www.onemedplace.com/forum/webcast.php at approximately 3:20 Eastern Daylight Time on Wednesday, June 30.

Biomoda recently completed patient enrollment and sample collection for the Phase II pilot study on its porphyrin-based compound as a diagnostic tool for early-stage lung cancer. The CyPath® labeling solution preferentially binds to cancer cells and causes them to fluoresce red under ultraviolet light. Pending Food and Drug Administration approval, CyPath® is for investigational use only. Biomoda is also pursuing a CE mark to commercialize CyPath® in the European Union.

The OneMedPlace Advisory Board said companies invited to participate in the mid-year forum at New York’s Roosevelt Hotel must have breakthrough technologies based on strong science, experienced management teams with a proven track record, strong and comprehensive IP portfolios, and partnerships with leading academic institutions and strategic players. “We are pleased to be included in this peer group,” Cousins said.

.

[pennyjoe]

.

bei den guten news muß man doch einfach nachlegen

.

[Alphatier]

News :

Biomoda President Interviewed by CorporateProfile.com

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD - News) (www.biomoda.com) announced today that a video interview with Biomoda President and CEO John Cousins has been posted at www.CorporateProfile.com.

Biomoda recently completed patient enrollment and sample collection for the Phase II pilot study on its porphyrin-based compound as a diagnostic assay for early-stage lung cancer. The CyPath® labeling solution preferentially binds to cancer cells and causes them to fluoresce red under ultraviolet light. Pending Food and Drug Administration approval, CyPath® is for investigational use only.

[pennyjoe]

.


Biomoda President Interviewed by CorporateProfile.com


2010-07-06 17:14 ET - News Release


ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) announced today that a video interview with Biomoda President and CEO John Cousins has been posted at www.CorporateProfile.com.

Biomoda recently completed patient enrollment and sample collection for the Phase II pilot study on its porphyrin-based compound as a diagnostic assay for early-stage lung cancer. The CyPath® labeling solution preferentially binds to cancer cells and causes them to fluoresce red under ultraviolet light. Pending Food and Drug Administration approval, CyPath® is for investigational use only.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, NM.

About CorporateProfile.com

CorporateProfile.com is a broadcasting website that provides a unique platform for investors to receive market tips and information in a less traditional, more entertaining format.

Forward-Looking Statements

etc......

.

[Alphatier]

Und schon wieder ein Patent :

Biomoda Files Patent Application

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD - News) (www.biomoda.com) filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

Biomoda’s CyPath® reagents for the early detection of cancers is based on meso-tetra (4 carboxyphenyl) porphine or TCPP, a porphyrin compound that binds to cancer cells and fluoresces under specific frequencies of light. The new patent application provides a system for verifying the spectral signature of TCPP optically and measuring the photon emission rate of TCPP-stained cancerous and precancerous cells.

“We now have an objective methodology that can be used by lab technicians anywhere in the world to accurately and inexpensively read CyPath® reagent-labeled tissue samples,” said Biomoda President John Cousins. “Previously, we had to rely on cytopathologists to look at each and every sample to determine whether there were cancer cells. This patent gives us a measurable, quantitative system that opens the door for the CyPath® assay to be used to screen large populations for cancer and pre-cancerous conditions. Diagnosing cancer even before a tumor has formed will have an exponential effect on survivability.”

Biomoda is nearing completion of the pilot study on the CyPath® assay as a diagnostic for early-stage lung cancer. Pending Food and Drug Administration approval, CyPath® reagents are for investigational use only.

Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the U.S. and foreign patent applications build on the science underlying Biomoda’s cytology-based diagnostic. Originally developed at Los Alamos National Laboratory, the TCPP platform is the foundation for several Biomoda product lines still in the development stage.

[pennyjoe]

Antwort auf Beitrag Nr.: 39.854.203 von Alphatier am 21.07.10 12:36:31

.

wenn die so weiter machen, wird das noch eine richtige erfolgsgeschichte

.

[karlik22]

Antwort auf Beitrag Nr.: 39.854.806 von pennyjoe am 21.07.10 14:16:09

Hallo
Ich habe vor einiger Zeit die Biomoda Zertifikate gekauft. Ich habe mir die Papiere einbuchen lassen. Die wurden unter folgenden WKN Nummer eingebucht-USU0904J2016. Dieser Nr. stimmt aber mit dem notierten Aktien (US0906271004)nicht überein. Weiss jemand wie kann ich diese Aktie auf die handelbare Aktie "umwandeln"?
KM

[Alphatier]

Antwort auf Beitrag Nr.: 40.145.016 von karlik22 am 14.09.10 08:06:42

Hallo
ich hatte das gleiche Problem - habe das Zertifikat über einen amerik. Anwalt und den Transferagenten + Hausbank freischalten lassen. Wenn Du willst kann ich Dir gerne per Boardmail die amerik. Kontakte mitteilen.

Hat super geklappt

[pennyjoe]

.

nicht schlecht - die kommenden monate sind gesichert

Biomoda Raises $560,000 Through Private Placement

2010-09-21 09:10 ET - News Release



ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) today announced that it has closed a private placement for gross proceeds of $560,000. Under the terms of the private placement, Biomoda has agreed to issue to investors (i) debentures convertible into shares of common stock and (ii) warrants to purchase 2,000,000 shares of common stock. The shares of common stock issuable upon conversion of the debentures and the exercise of warrants are restricted under Securities and Exchange Commission (SEC) Rule 144.

The convertible debentures will mature on August 31, 2011. The convertible debentures will bear interest at an annual rate of 10 percent of the principal amount of the debentures outstanding from time to time, payable in cash on the earlier of the conversion of the debenture or the maturity date.

“Continued support from the life-sciences investment community will help us bring our diagnostic for early-stage lung cancer to the marketplace,” said Biomoda President John Cousins. “Proceeds from this financing will be used to fund operations as we finalize the analysis of data from our pilot clinical study and prepare to launch the pivotal study, the final step before FDA approval.”

Biomoda’s CyPath® diagnostic assay binds to cancer cells and causes them to fluoresce under specific frequencies of light. Pending FDA approval as a Class III medical device, CyPath® is for investigational use only.

The securities described above were sold by Biomoda to non-affiliates in a private placement under Rule 144, a safe harbor that allows for the sale of restricted and affiliate securities in limited quantities without requiring the securities to be registered. This press release does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities.

us$ 0,28 incl. warrants ist ok - nur mit den 10% das habe ich noch nicht verstanden.

.

[Kursziel1000]

on watch

[Kursziel1000]

Biomoda anstehenden Daten zu Cypath rücken immer näher

04.10.2010
Global Biotech Investing

Endingen (aktiencheck.de AG) - Sobald die Aktie von Biomoda (ISIN US0906271004 / WKN A0MSTL) anspringt, muss man als Anleger dabei sein, raten die Experten von "Global Biotech Investing".

Bei Biomoda würden die anstehenden Daten zu Cypath immer näher rücken. Bei Cypath handle es sich um ein nicht-invasives Testverfahren zur Früherkennung von Lungenkrebs. Es sei der vielversprechendeste Produktkandidat von Biomoda. Sollte die Phase II-Studie erfolgreich verlaufen, würden die Analysten von LifeTech für Ende des Jahres die Aufnahme einer pivotalen Phase III-Studie erwarten.

Anzeige

Ab 2011 würden die Analysten von LifeTech erstmals Umsätze aus Cypath erwarten. Für 2012 würden sie bei Umsätzen von 3 Mio. USD den Break-even prognostizieren. Für 2013 würden sie dann mit einem Umsatzsprung auf 18 Mio. USD sowie einem Nettogewinn von 10,3 Mio. USD bzw. von 0,08 USD je Aktie rechnen. Damit sei der Titel lediglich mit einem KGV 2013e von 2,5 bewertet.

Bisher sei das Papier vom Markt noch nicht entdeckt worden.

Sobald die Aktie von Biomoda anspringt, muss man als Anleger dabei sein, empfehlen die Experten von "Global Biotech Investing". (Ausgabe 19 vom 04.10.2010) (04.10.2010/ac/a/a)

[pennyjoe]

.

bin dabei

.

[pennyjoe]

.

Biomoda Extends Pilot Trial on Lung Cancer Diagnostic

2010-10-07 09:05 ET - News Release



ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) today announced in its new monthly President’s Column, posted at www.biomoda.com, that it is extending the pilot clinical trial of its CyPath® diagnostic assay for the detection of early-stage lung cancer to recruit additional participants for the positive control group, patients who have been diagnosed with lung cancer but have not yet begun treatment for the disease.

“The primary purpose of the pilot trial is to assess the specificity and sensitivity of the CyPath® assay and generate sufficient data to move forward with the pivotal clinical trial,” Biomoda President John Cousins said. “The positive control group is critical to assessing the sensitivity of the CyPath® assay. We have had to exclude samples from a significant number of participants in the positive control group from our analysis. Consequently, we plan to add at least one additional enrollment site to expedite recruitment and completion of the study.”

Cousins acknowledged that identifying patients to participate in the positive control group has been a challenge. “It has been difficult to recruit diagnosed pre-treatment patients who are able and willing to give their truly precious time to our study. We thought we had secured sufficient samples, but further investigation showed that some of these lung cancer patients do not fit the FDA-approved criteria for inclusion in the positive control group. Some of the patients’ cancer is located outside the lung cavity. Under the protocol submitted to the FDA, these patients must be excluded from the study,” Cousins said in his President’s Column (posted at www.biomoda.com) updating the status of the clinical trial and other company activities.

“We are still confident the results of our lung cancer pilot study will be more than sufficient to lay the foundation for our pivotal study,” said Cousins.

Biomoda’s CyPath® labeling solution for the early detection of cancers binds to cancer cells and fluoresces under specific frequencies of medium light. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

.

[pennyjoe]

.

da wird das bäumchen aber kräftig geschüttelt

nachkaufen oder aussitzen - das ist hier die frage

.

[Kursziel1000]

Antwort auf Beitrag Nr.: 40.283.443 von pennyjoe am 07.10.10 17:26:57

Kursziel $1
http://www.lifetechcapital.com/reports/BMOD%20Update%2010-07…

[Kursziel1000]

http://www.lifetechcapital.com/reports/BMOD%20Update%2010-07…

[pennyjoe]

Antwort auf Beitrag Nr.: 40.285.909 von Kursziel1000 am 07.10.10 23:37:23

.

sehr klare stellungnahme und äusserst informative darstellung der firma mit den chancen

danke

.

[Kursziel1000]

[Kursziel1000]

(RTTNews) - The U.S. Food and Drug Administration has announced a plan to spend millions of dollars in order to update its tools for "regulatory science" agenda, which includes reviewing prescription drugs, medical devices and tracking food safety.

The new proposal, titled "Advancing Regulatory Science for Public Health," was released Wednesday by the agency's leaders.

The plan calls for the agency to spend the $25 million allocated within its budget for pilot studies on research in key areas including the use of biomarkers for personalized medicine, better data collection on outcomes for medical devices, and learning how to scientifically assess new technologies in FDA-regulated products.

The agency's total budget is proposed to be $4 billion, but Congress has yet to approve it.

All of the investments are aimed at keeping pace with rapid changes in science and technology.

"We need new approaches, new collaborations and new ways to take advantage of 21st century technologies," the FDA said in its announcement.

"There is no single discovery -- no magic bullet -- to address our unique set of modern scientific regulatory challenges," the agency wrote. "But one thing is clear: if we are to solve the most-pressing public health problems we face today, we need new approaches, new collaborations and new ways to take advantage of 21st century technologies."

by RTT Staff Writer
http://www.rttnews.com/Content/HealthNews.aspx?Id=1440052&SM…

[Kursziel1000]

Antwort auf Beitrag Nr.: 40.287.134 von pennyjoe am 08.10.10 10:15:04

Was ist eigentlich mit dem Listing in Frankfurt geworden?

[pennyjoe]

.

jetzt müßte man noch freies kapital haben - der preis ist eine lachnummer

.

[Alphatier]

Leider wurd schon wieder bei den präklinischen Tests geschlampt, so wies aussieht. Diesen Lapsus dürfte man sich eigentlich nicht erlauben. Schade fürs Unternehmen - wäre ansich sehr erfolgversprechend.

[Alphatier]

Aber sie "zappeln" noch - vielleicht keine schlechte Zeit einzusteigen :


Biomoda Receives $244,479 Grant for Therapeutic Discovery Project

11.01.2010 — 1:00 pm

ALBUQUERQUE, N.M.– Cancer diagnostics company Biomoda, Inc. (OTC BB:BMOD.ob) announced receipt of $244,479 in federal grant funding for its CyPath® diagnostic assay for the detection of early-stage lung cancer. The Internal Revenue Service issued the funding under the Qualifying Therapeutic Discovery Project administered under section 48D of the Internal Revenue Code.

“The funds will be directly applied towards completion of our pilot clinical trial and initiation of the pivotal clinical trial leading to commercialization of our technology,” said Biomoda President and Chief Executive Officer John Cousins.

Biomoda’s CyPath® labeling solution for the early detection of cancers binds to cancer cells and fluoresces under specific frequencies of medium light. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only.

The Qualifying Therapeutic Discovery Project, enacted as part of the Patient Protection and Affordable Care Act of 2010, is designed to provide grants or tax credits to qualified biotechnology companies that demonstrate the potential to:

* Develop new therapies to treat chronic conditions or unmet medical needs,
* Reduce long-term health care costs in the United States, or
* Significantly advance the goal of curing cancer within 30 years.

“We are pleased that the Department of Health and Human Services and the IRS recognized Biomoda’s potential to address all three of these very significant goals. I also want to thank the New Mexico congressional delegation for their long-term commitment to creating new jobs and protecting small business in our state,” Cousins said.

[Kursziel1000]

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) has allied with Quintiles Global Central Laboratories (www.quintiles.com) to help refine the automated image recognition system for measuring the photon emission rate and cell morphology of CyPath®-stained cells to detect early stage lung cancer.

“One of the key prerequisites prior to commercialization is a highly accurate, fully automated system for reading the assay with state-of-the-art digital technology,” Biomoda President John Cousins said. “Quintiles is the perfect partner for us as we develop our own expert system of digital cytopathology for cancer cell identification. Their in-house pathology capabilities and expertise in tissue-based testing are second to none.”

“We look forward to harnessing innovative pathology and digital technologies with Biomoda to streamline and improve the selection of cancer patients in the New Health,” said Christopher Ung, Vice President, Strategic Business & Operations, Oncology, Quintiles. “Quintiles is committed to alliances that support advances in personalized medicine and the development of safer, more effective targeted therapies.”

Biomoda’s CyPath® labeling solution for the early detection of cancers binds to cancer cells and fluoresces under specific frequencies of medium light. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath® is for investigational use only.

Under the terms of the agreement, Quintiles will review CyPath®-stained slides and pap-stained slides to analyze the cell matrices and help Biomoda further calibrate the “signature” of cancer and other aberrant cells that have been labeled with the CyPath® solution.

Quintiles develops proprietary and novel biomarker tests for analyzing genes and proteins that affect cancer cell growth and mutation, and performs these assays at labs in the United States, Scotland and China. Quintiles has the largest and now entirely CAP-accredited central laboratory network in the world, with wholly owned facilities in the United States, Europe, South Africa, India, China, Singapore and Japan, and a tightly controlled network of affiliate laboratories in Argentina and Brazil.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

[Alphatier]

Antwort auf Beitrag Nr.: 40.523.483 von Kursziel1000 am 15.11.10 15:51:51

Das wird wohl so schnell nix mehr - schade.

[pennyjoe]

.

bei 0,05us$ könnte man sich mal wieder 100 stück ins depot legen :-)

.

[geldspender]

Heute kommt eine Kaufempfehlung von Börse Inside, nicht immer positiv
aber dadurch wurde ich auf diese Aktie aufmerksam, werde Sie mal beobachten.

[pennyjoe]

.

nach dem hype der letzten wochen ist es schade, dass es heute so runtergeht.

.

[Alphatier]

Antwort auf Beitrag Nr.: 41.291.003 von pennyjoe am 30.03.11 17:43:49

Wohl schon wieder paar Pusher unterwegs gewesen.
Die Anleger sind nicht mehr so doof wie früher - hoffentlich.

[pennyjoe]

.

Biomoda Collaborates with UT Health Science Center at San Antonio

2011-03-31 10:37 ET - News Release



Company Website: http://www.biomoda.com
ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) today announced the signing of a Memorandum of Understanding with the University of Texas Health Science Center at San Antonio to collaborate on research to optimize the CyPath® diagnostic assay for lung cancer.

“UT Health Science Center in San Antonio is a world-class biomedical research and education institution with a proven track record of turning scientific research into clinical practice,” said Biomoda CEO Maria Zannes. “We will benefit from the Health Science Center’s extensive resources for our ongoing optimization work in preparation for the multi-site pivotal trial. We also intend to tap into the economic grant programs and research funding afforded by this initiative.”

Health Science Center Vice President for Research Dr. Brian Herman said, “We will be working with Biomoda to bring its cancer diagnostic tests to the front end of medical treatment in order to use medical expertise and resources as efficiently and effectively as possible.”

“Our research will progress more quickly and our science will be strengthened by this initiative,” said Biomoda President John Cousins. “Biomoda is focused on optimization of its assay to include automating sample reading through flow cytometry and refining the use of fluorescent microscopy to identify cancer cell types and pre-cancerous cells. The Health Science Center not only will greatly assist us with the science, but we believe the partnership has the potential to create jobs and economic growth for the region.”

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

About UT Health Science Center at San Antonio

One of the country’s leading health sciences universities, The University of Texas Health Science Center at San Antonio ranks in the top 3% of all institutions worldwide receiving federal funding. The Health Science Center performs biomedical research focused on accelerating, facilitating, and increasing the discovery, development, and dissemination of biomedical solutions that improve the quality of life.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, which are described from time to time in the Company’s filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice

.

[pennyjoe]

.

jetzt sind wir fast wieder bei den us$ 0,05, wo sich eventuell ein einstieg lohnen könnte.

ich habe immernoch nicht den grund für den extremen rücksetzer gefunden, aber wenn es anschließend wieder auf us$ 0,23 hochgeht, soll mir das auch egal sein.

.

[pennyjoe]

.

ich bin wieder an bord:

Press Release Source: Biomoda, Inc. On Tuesday April 5, 2011, 9:20 am EDT

ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- The chief executive officer of cancer diagnostics company Biomoda, Inc. (OTCBB:BMOD.ob - News) (www.biomoda.com) discussed top-line results of the company’s pilot clinical trial of the CyPath® diagnostic for lung cancer on nationally syndicated business radio talk shows airing on the Business Talk Radio Network (www.businesstalkradio.net/) and the Radio America Network (www.radioamerica.org) as well as Money Matters Radio (www.moneymattersradio.net) in the Boston market.



“Most important for Biomoda and the medical community, we have determined that CyPath® is a significant new biomarker for lung cancer,” Biomoda CEO Maria Zannes told listeners. She outlined ongoing optimization work that the company believes will improve the sensitivity and specificity of the assay, including research in collaboration with the University of Texas Health Science Center at San Antonio.



“Equity Strategies,” the nationally syndicated business broadcast, and “Stu Taylor on Business,” a morning drive-time Boston broadcast, are anchored by business talk show host Stu Taylor. Broadcasts featuring interviews with Zannes and Biomoda President John Cousins are archived on the Biomoda website.



About Biomoda



Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.



Forward-Looking Statements



This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, which are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2011. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

.

[pennyjoe]

.

das waren die news von gestern:

Press Release Source: Biomoda, Inc. On Monday April 4, 2011, 10:49 am EDT

ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- Cancer diagnostics company Biomoda, Inc. (OTCBB:BMOD.ob - News) (www.biomoda.com) today announced that LifeTech Capital has updated its independent research coverage on Biomoda based on top-line results of the pilot clinical trial of Biomoda’s CyPath® diagnostic assay for lung cancer.



LifeTech recommends Biomoda as a “Strong Speculative Buy” stating the company’s pilot trial demonstrates proof of concept, provides “best results yet for lung cancer screening” and does not expose patients to ionizing radiation. The report was written by Stephen M. Dunn, Senior Managing Director, Research, and William D. Dawson, Senior Vice President, Research, for LifeTech Capital, a division of Aurora Capital LLC, and is available online at www.lifetechcapital.com/reports.htm.



LifeTech Capital is an investment bank that specializes in the biotechnology and medical technology industries. Biomoda does not endorse the reports, projections or statements of any analyst.



About Biomoda



Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.


sollte doch mit dem teufel zugehen, wenn wir heute nicht den boden gesehen haben

ist natürlich nur meine persönliche meinung, denn bei diesem wert muß jeder selber entscheiden.....

.

[pennyjoe]

.

das war kein aprilscherz, aber ohne diesen shortseller-angriff wäre ich nicht nochmal so günstig an biomoda gekommen

Date: Apr 1, 2011
Even though Biomoda, Inc. (OTC:BMOD, BMOD message board) issued the promised update on the pilot study of its CyPath cancer detection method, the company's stock crashed down ruthlessly on a record high volume. The last two days BMOD got trapped in a 50% and 20% decline of the stock value, which wiped out the 280% gain achieved in the last month.
In fact, the last few weeks the company was markedly turning into sorters' favorite with short sales exceeding 50% of the traded volume. Only after the stock value plummeted, did the short selling subside down to 20%.


Even the company's statement that the pilot study of CyPath showed encouraging results couldn't prevent shorters from rejoicing. Its seems that technical analysis and day trading have taken rule over BMOD session these days.

Now that the stock has retracted back to its previous trading channel, the most important question is where will it head next. With short sales having dropped down, it seems that the chances for further depreciation had already been soaked up. However, the company's financial documents show that BMOD is primarily relying on common stock issuance to provide cash and brings forth the looming image of dilution into the stock play.

Therefore, in the coming days the direction of the stock will most likely be under the influence of short-term traders' mood

.

[pennyjoe]

.

den absoluten tiefstpunkt zu treffen, ist fast unmöglich.
aber ich habe den eindruck, dass sich hier bei ca us$ 0,07 ein boden bildet.
m.m.n. hat die firma in den vergangenen monaten und jahren bewiesen, das sie ihre ziele kosequent verfogt und in der lage ist diese ausserordentlichen patente gewinnbringend für die aktionäre in die produktion zu führen.
fast alle krankenkassen der welt ächtsen unter zu hohen kosten und m.w.n. gibt es noch keinen vergleichbar günstigen schnelltest für lungenkrebs mit dieser treffsicherheit.

wir werden sehen, wie es in den kommenden wochen weitergeht.

.

[pennyjoe]

.

es lohnt auf jedenfall biomoda heute und morgen nicht aus den augen zu lassen

http://www.americanbulls.com/StockPage.asp?CompanyTicker=BMO…

.

[Alphatier]

Antwort auf Beitrag Nr.: 41.333.537 von pennyjoe am 07.04.11 13:09:25

Scheint so, als ob sich da so schnell nix mehr tut.

Eine sog. "gute" News sollte eigentlich schon den Kurs beflügeln.

Bei Biomoda siehts irgendwie nicht so aus. Komisch.

[pennyjoe]

.

es wird schon noch einpaar tage dauern, bis wir die alten höchststände wiedersehen

.

[pennyjoe]

.

das sollte der boden gewesen sein

http://www.americanbulls.com/StockPage.asp?CompanyTicker=BMO…

.

[pennyjoe]

.

ich finde es wäre an der zeit, dass der vorstand oder die prabteilung etwas zu dem extremen kursverfall veröffentlicht.

.

[pennyjoe]

.

ich hoffe, dass die shorties jetzt wieder raus sind und die firma bald news rausbringen, wie es weitergeht.

.

[pennyjoe]

.

vor einpaar tagen habe ich eine anfrage gemailt, ob es eine erklärung für den plötzlichen kursverfall gibt, hier die antwort:

dear mr. .......

As an investor, you know the public markets are often difficult to predict. Many factors above and beyond the technological progress and operating fundamentals of a company can influence share price. We do not believe that our stock performance of late accurately reflects recent news and the Company’s results. Other investors and third-party investment strategies can influence the stock price of any public company, including Biomoda.



Creating sustainable shareholder value in any type of market environment requires a strong foundation, one grounded in strategic vision and operations. We continue to believe that the results of our pilot study provide a solid foundation from which we can progress to commercialization of the CyPath non-invasive, inexpensive cancer diagnostic that has the potential to significantly increase survival rates for lung cancer.



We also believe that Biomoda represents an investment value and that there is a significant difference between our current market capitalization and the enterprise value of Biomoda based on our technology and the size of our potential markets. Even minimal market penetration results in revenues in the hundreds of millions of dollars. The present value of these projected revenues is a big multiple of our current market cap.



As a public company, Biomoda is obligated to provide material information to all investors. Please refer to the quarterly report on Form 10-Q that will be filed on the SEC’s EDGAR system in May for additional information on recent pressures on the share price. In the meantime, we are investigating near-term financing opportunities to relieve current pressure on the stock and provide capital to continue with ongoing research and development on CyPath.



We are grateful to those investors who see the benefit and have the vision to stand with us in support of our technology.



Best regards,
Julie Anne Overton
Investor Relations

[pennyjoe]

.



wann kommt die wende?

.

[pennyjoe]

.

könnte vielleicht doch noch was werden:

Biomoda Expands IP Portfolio with Canadian Patent, Trademark Protection in EU

2011-05-17 07:10 ET - News Release



Company Website: http://www.biomoda.com
ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) today announced significant additions to its Intellectual Property (IP) portfolio, including a Canadian patent for using its proprietary porphyrin-based compound to detect cancer and trademark protection for Biomoda’s CyPath® assay kits and reagents in the European Union.

“While we work toward FDA approval and commercialization of our CyPath® diagnostic for lung cancer, it is critically important to make sure that our technology and the IP behind it are protected,” Biomoda President John Cousins said. “Cancer is a global health crisis with the number of diagnoses and deaths expected to double by 2030. We will continue to expand the geographic reach of our IP protection in order to make the CyPath® assay available worldwide.”

The Canadian Intellectual Property Office issued Canadian patent 2,429,526 titled “Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine.” The Canadian patent is similar to Biomoda’s U.S. patent 6,838,248, which was issued in 2005. Biomoda now has foreign patent rights in Canada, Mexico, Japan and Australia. Patent rights are pending before the European Patent Office.

The World Intellectual Property Organization (WIPO), an agency of the United Nations headquartered in Geneva, has issued a Certificate of Registration that provides trademark protection for CyPath® kits and reagents for clinical and laboratory diagnostic use in the European Union (EU).

“Trademark protection is a key step toward filing for a CE mark in Europe,” Biomoda CEO Maria Zannes said. “One strategy we are exploring is using CyPath® as a screening tool in Europe. We believe this would both expedite our path to market and provide additional data for our pivotal clinical trial.”

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

Forward-Looking Statements

.

[Alphatier]

Mir sieht das langsam eher nach den letzten Flügelschlägen aus.

Nur gute PR nutzt nicht viel.

[pennyjoe]

.
2011-06-14 09:18 ET - News Release



Company Website: http://www.biomoda.com
ALBUQUERQUE, N.M. -- (Business Wire)

Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath® assay to include patient response to cancer therapy during the treatment phase of the disease.

“Our pilot clinical study demonstrated the CyPath® assay’s utility as a cancer diagnostic. We expect the unique properties of the CyPath® labeling solution that allow it to bind to cancer cells and cause them to fluoresce can also play a significant role in determining the efficacy of cancer treatment,” Biomoda President John Cousins said. “Doctors will be able to take fluid or tissue samples at intervals during chemotherapy, treat them with the CyPath® solution and compare the results to the baseline assay to see if the percentage of cancerous and abnormal cells is moving in the right direction.”

Titled “Method for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis (Carboxyphenyl),” U.S. Patent 7,960,138 is a continuation of Biomoda’s U.S. Patent 6,838,248, titled “Compositions and Methods for Detecting Pre-Cancerous Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine” which was issued on Jan. 4, 2005.

“One of Biomoda’s principal assets is our strong patent portfolio,” Biomoda CEO Maria Zannes said. “This patent continues our dual commitments to protecting our intellectual property and expanding our product lines to include innovative tools for each step of the way, from early diagnosis to successful treatment, in the fight against cancer.”

Biomoda has four U.S. patents and foreign patent rights in Canada, Japan, Mexico and Australia. Patent rights are pending before the European Patent Office.

About Biomoda

Biomoda (www.biomoda.com) is focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially due to a variety of factors, which are described from time to time in the Company’s filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2011. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

.

[pennyjoe]

.

da kann keiner behaupten, die firma käme nicht voran:


Albuquerque, NM (July 6, 2011) – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received notification that the Japan Patent Office has granted the company’s patent application related to a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light to detect cancer and pre-cancerous cells in body fluid and tissue samples.

“There are more than 30 million smokers in Japan, and although smoking rates have actually declined since 2008, lung cancer is the leading cause of cancer deaths in Japan,” Biomoda President John Cousins said. “The market for an early-stage lung cancer diagnostic like our CyPath® assay is truly global.”

Japanese Patent Application No. 2008-266490, “Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,” is similar to Biomoda’s U.S. patent 6,838,248, which was issued in 2005. Foreign equivalents are now effective in Canada, Mexico, Japan and Australia and pending before the European Patent Office.

“We have proactively sought to protect our intellectual property on an international level,” Biomoda CEO Maria Zannes said. “Our patent portfolio is the foundation of our strategy to significantly impact the five-year survival rate for lung cancer by giving doctors throughout the world access to a non-invasive, inexpensive and accurate diagnostic.”

Biomoda completed the pilot clinical trial of the CyPath® assay in March 2011 and plans to seek Food and Drug Administration approval of its cytology-based diagnostic technology as a medical device. Pending FDA approval, CyPath® is for investigational use only.
The Japan Patent Office cooperates with the US Patent and Trademark Office and the European Patent Office as one of the Trilateral Patent Offices, a cooperative program established to improve the efficiency of the global patent system.


kaufen und liegenlassen

.

[pennyjoe]

.

Ich glaube jetzt fehlt nur noch china - aber da zählen patente ja sowieso nix


European Patent Office To Grant Biomoda Patent

Albuquerque, NM (Aug. 2, 2011) – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received notification from the European Patent Office (EPO) of its intention to grant the company’s patent application related to a method of using Biomoda’s proprietary porphyrin-based compound to detect cancer and pre-cancerous cells in body fluid and tissue samples.

“According to the World Health Organization, there are 215 million current smokers in the European Union and tobacco is the leading contributor to the disease burden in more than half the EU countries,” Biomoda President John Cousins said. “The potential European market for the CyPath® diagnostic assay is five times the U.S. market, representing a significant revenue stream post-commercialization of the technology. With the EPO patent, we may be able to launch CyPath® as a screening tool in Europe and start collecting revenue from sales prior to FDA approval in the U.S.”

European Patent Application No. 01987011.2, “Composition and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,” is similar to Biomoda’s U.S. patent 6,838,248, which was issued in 2005. Foreign equivalents are also effective in Canada, Mexico, Japan and Australia.

“The EPO is committed to high standards for quality and innovation,” Biomoda CEO Maria Zannes said. “The EPO’s decision to grant our patent is an important addition to our patent portfolio and may open the door to additional sources of funding to continue our push toward FDA approval and commercialization.” The European Patent Office cooperates with the U.S. Patent and Trademark Office and the Japan Patent Office as part of a cooperative program established to improve the efficiency of the global patent system.

[pennyjoe]

.

irgendwann gibt es hier einen knall und wir lassen selbst die alten höchststände hinter uns .......

.

[pennyjoe]

In the August 2011 President’s Column, Biomoda President John Cousins discusses plans for the European market and Biomoda’s continuing efforts to raise the financing necessary to complete clinical trials and commercialize the CyPath® diagnostic assay. We welcome questions from investors. Please submit questions to [e-mail].

What is the potential impact of the European patents?

Biomoda wholly owns the patents and trademarks for our technology and products under development, and our intellectual property is one of our most valuable assets. Recent news from the European Patent Office (EPO) that it would be granting our patents in the European countries we select will increase the value of our patent portfolio significantly. The path to commercialization in Europe can be quicker than the parallel process in the U.S., which means the European patents can help us achieve revenues sooner than commercialization in the U.S. only.

According to the World Health Organization, there are 215 million current smokers in Europe. In contrast, the Centers for Disease Control reports an estimated 46 million Americans smoke cigarettes, the leading cause of lung cancer worldwide. This means that the potential European market for the CyPath® assay is nearly five times the U.S. market. The EPO patent protects our porphyrin-based assay in a market that represents more than 850 million people.

We are also in the process of obtaining a CE mark. The letters “CE” stand for “Conformité Européenne” or “European Conformity,” and the CE mark is a key indicator of a product’s compliance with European Union legislation and standards. Medical devices like the CyPath® assay are one of the product categories which require a CE mark to be marketed throughout the European Economic Area (EEA). Medical devices not only have to meet safety, health and environmental protection standards but must also function in a medical-technical way as described in the manufacturer’s “intended purpose.”

The CE mark will allow Biomoda to market the CyPath® assay in the EEA, with or without U.S. Food and Drug Administration (FDA) approval. The significant stream of revenue that can come from European sales prior to FDA approval and commercialization in the U.S. market makes the company more attractive to investors at this stage of our development.

Can you update on the status of Biomoda’s efforts to raise additional capital?

Until Biomoda is able to generate revenue from sales of our diagnostic assay, we are a development-stage company. The biggest challenge development-stage companies face, particularly in a tough economy when potential investors are more cautious about their investments, is raising adequate capital to move their promising technologies through research and development and regulatory approval into the marketplace.

This is the situation in which we find ourselves today. Although we reported positive news from our pilot clinical trial which demonstrated that CyPath® is a significant bio-marker for lung cancer, contractual obligations related to warrants and notes associated with institutional investments that provided operating capital for the Company in 2010 negatively impacted the stock price and substantially increased our obligation to issue common shares of stock. It is safe to say that both of those factors have hurt our ability to raise new funding.

We remain committed to moving forward. Biomoda’s Chief Executive Officer, Maria Zannes, and I are joined by key employees who work hard every day to evaluate strategic investment options. We have reviewed several proposals from potential investors and continue to do so. These investors, like us, see CyPath®’s potential as an inexpensive, non-invasive, accurate diagnostic for lung cancer which could become a standard tool in the medical arsenal in the war against cancer. For more information, you may want to refer to our quarterly financial statement filed on August 19, 2011, with the U.S. Securities and Exchange Commission (SEC).

When is the shareholder meeting?

In the first week of September, Biomoda will mail shareholders notice of our annual shareholder meeting to be held September 16, 2011, at 2 pm Mountain time at Biomoda’s headquarters in Albuquerque, New Mexico. Shareholders will be asked to approve an increase in authorized shares that will provide for raising capital through the sale of stock. Increasing authorized shares can be viewed as a dilutive event, but in our case I believe it will result in increased value by providing the money needed to move forward and commercialize the technology. The shareholder notice also will include recommendations to vote in favor of the current slate of Directors and to approve our auditors, GBH CPAs, PC, a national SEC audit firm located in Houston, Texas.

[pennyjoe]

.

NEWS:

Biomoda Files New Patent Application
To Optimize CyPath® Assay


Albuquerque, NM (Nov. 2, 2011) – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath® diagnostic assay for lung cancer.

“This patent is based on a proprietary solid-state, diode-based light source for fluorescent microscopy that will improve our ability to differentiate between cancer cells and the so-called debris and artifacts found at the cellular level in tissue and body samples,” Biomoda President John Cousins said. “By stabilizing the excitation mechanism and reducing variations in the way we measure photonic emissions from cells, this invention simultaneously increases our accuracy and reduces costs associated with the current technology.”

The porphyrin-based CyPath® assay binds to cancer cells and causes them to fluoresce under specific frequencies of light. The pilot clinical study concluded in March 2011 demonstrated that CyPath® is a significant new biomarker for lung cancer.

“This technical breakthrough is the result of our optimization studies to improve the sensitivity and specificity of our assay,” Biomoda CEO Maria Zannes said. “Biomoda’s intellectual property is our core asset, and we expect to continue to build our patent portfolio with innovations like this one.”

Biomoda has four U.S. patents and foreign patent rights in Europe, Canada, Japan, Mexico and Australia.

About Biomoda
Biomoda (www.biomoda.com) is focused on the development of accurate, inexpensive and non-invasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.

.

[meiramgul]

Tausche Astelcom gegen Biomoda...